<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5869493</article-id><article-id pub-id-type="doi">10.3390/v10030100</article-id><article-id pub-id-type="publisher-id">viruses-10-00100</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>DNA Vaccine-Encoded Flagellin Can Be Used as an Adjuvant Scaffold to Augment HIV-1 gp41 Membrane Proximal External Region Immunogenicity </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ajamian</surname><given-names>Lara</given-names></name><xref ref-type="aff" rid="af1-viruses-10-00100">1</xref><xref ref-type="aff" rid="af2-viruses-10-00100">2</xref></contrib><contrib contrib-type="author"><name><surname>Melnychuk</surname><given-names>Luca</given-names></name><xref ref-type="aff" rid="af1-viruses-10-00100">1</xref><xref ref-type="aff" rid="af2-viruses-10-00100">2</xref></contrib><contrib contrib-type="author"><name><surname>Jean-Pierre</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="af1-viruses-10-00100">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0656-0714</contrib-id><name><surname>Zaharatos</surname><given-names>Gerasimos J.</given-names></name><xref ref-type="aff" rid="af1-viruses-10-00100">1</xref><xref ref-type="aff" rid="af3-viruses-10-00100">3</xref><xref rid="c1-viruses-10-00100" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-viruses-10-00100"><label>1</label>Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC H3T 1E2, Canada; <email>lara.ajamian@mail.mcgill.ca</email> (L.A.); <email>luca.melnychuk@mail.mcgill.ca</email> (L.M.); <email>patjp2106@gmail.com</email> (P.J.-P.)</aff><aff id="af2-viruses-10-00100"><label>2</label>Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, QC H4A 3J1, Canada</aff><aff id="af3-viruses-10-00100"><label>3</label>Division of Infectious Disease, Department of Medicine &amp; Division of Medical Microbiology, Department of Clinical Laboratory Medicine, Jewish General Hospital, Montréal, QC H3T 1E2, Canada</aff><author-notes><corresp id="c1-viruses-10-00100"><label>*</label>Correspondence: <email>gerasimos.zaharatos@mcgill.ca</email>; Tel.: +1-514-340-8294</corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2018</year></pub-date><volume>10</volume><issue>3</issue><elocation-id>100</elocation-id><history><date date-type="received"><day>28</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>23</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement>© 2018 by the authors.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>Flagellin’s potential as a vaccine adjuvant has been increasingly explored over the last three decades. </plain></SENT>
<SENT sid="2" pm="."><plain>Monomeric flagellin proteins are the only known agonists of Toll-like receptor 5 (TLR5). </plain></SENT>
<SENT sid="3" pm="."><plain>This interaction evokes a pro-inflammatory state that impacts upon both innate and adaptive immunity. </plain></SENT>
<SENT sid="4" pm="."><plain>While pathogen associated molecular patterns (PAMPs) like flagellin have been used as stand-alone adjuvants that are co-delivered with antigen, some investigators have demonstrated a distinct advantage to incorporating antigen epitopes within the structure of flagellin itself. </plain></SENT>
<SENT sid="5" pm="."><plain>This approach has been particularly effective in enhancing humoral immune responses. </plain></SENT>
<SENT sid="6" pm="."><plain>We sought to use flagellin as both scaffold and adjuvant for HIV gp41 with the aim of eliciting antibodies to the membrane proximal external region (MPER). </plain></SENT>
<SENT sid="7" pm="."><plain>Accordingly, we devised a straightforward step-wise approach to select flagellin-antigen fusion proteins for gene-based vaccine development. </plain></SENT>
<SENT sid="8" pm="."><plain>Using plasmid DNA vector-based expression in mammalian cells, we demonstrate robust expression of codon-optimized full length and hypervariable region-deleted constructs of Salmonella enterica subsp. enterica serovar Typhi flagellin (FliC). </plain></SENT>
<SENT sid="9" pm="."><plain>An HIV gp41 derived sequence including the MPER (gp41607–683) was incorporated into various positions of these constructs and the expressed fusion proteins were screened for effective secretion, TLR5 agonist activity and adequate MPER antigenicity. </plain></SENT>
<SENT sid="10" pm="."><plain>We show that incorporation of gp41607–683 into a FliC-based scaffold significantly augments gp41607–683 immunogenicity in a TLR5 dependent manner and elicits modest MPER-specific humoral responses in a mouse model. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>HIV-1</kwd><kwd>gp41</kwd><kwd>membrane proximal external region</kwd><kwd>MPER</kwd><kwd>flagellin</kwd><kwd>adjuvant</kwd><kwd>DNA vaccine</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec id="sec1-viruses-10-00100"><title><text><SENT sid="11" pm="."><plain>1. </plain></SENT>
<SENT sid="12" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="13" pm="."><plain>Despite the tremendous success generated by an empiric approach to vaccine development, eliciting robust and long-lasting protective immunity to certain pathogens remains challenging [1,2]. </plain></SENT>
<SENT sid="14" pm="."><plain>While live attenuated virus vaccines have remarkable efficacy, this is not a solution for all pathogens either because they cannot be safely attenuated or because natural infection does not confer protective immunity [2,3,4,5,6,7,8,9]. </plain></SENT>
<SENT sid="15" pm="."><plain>Purified protein or recombinant subunit vaccines have provided a way forward in some instances, however the immunogenicity of such antigens is often poor or vaccination simply does not generate the type of immune response required for protection [10,11]. </plain></SENT>
<SENT sid="16" pm="."><plain>In some instances, the magnitude, longevity or quality of the immune response to such antigens has been improved by using adjuvants, however the mechanism of adjuvant function has been ill-defined for most adjuvants [10,11]. </plain></SENT>
</text></p><p><text><SENT sid="17" pm="."><plain>The discovery of pathogen associated molecular patterns (PAMPs), particularly ligands for Toll-like receptors (TLRs) have revolutionized our understanding of innate immunity and ushered in a new era of rational adjuvant development [10,12,13]. </plain></SENT>
<SENT sid="18" pm="."><plain>One promising avenue of adjuvant research has stemmed from work with the Toll-like receptor 5 (TLR5) ligand flagellin. </plain></SENT>
<SENT sid="19" pm="."><plain>Polymerized flagellin proteins are the major component of the flagellar apparatus of motile gram-negative and gram-positive bacteria [14]. </plain></SENT>
<SENT sid="20" pm="."><plain>Monomeric flagellin proteins are the only known agonists of TLR5 [15] and a large body of work has explored the interaction between the major Salmonella flagellin protein, FliC and TLR5 [16,17,18,19,20,21,22]. </plain></SENT>
<SENT sid="21" pm="."><plain>TLR5 is expressed on a variety of cells including epithelial cells, monocytes and dendritic cells [21,23]. </plain></SENT>
<SENT sid="22" pm="."><plain>Flagellin interacts with TLR5 on the cell surface in a 2:2 complex and induces dimerization of flagellin-TLR5 pairs [24,25]. </plain></SENT>
<SENT sid="23" pm="."><plain>The resulting dimerization of the intracellular TIR domains of TLR5 activate downstream signaling pathways. </plain></SENT>
<SENT sid="24" pm="."><plain>This includes a MyD88-dependent signalling cascade that culminates in the induction of transcription factors, including NF-κB [16,17,18,19,20,21,22,26]. </plain></SENT>
<SENT sid="25" pm="."><plain>In turn, these transcription factors upregulate cytokine transcription and ultimately evoke a pro-inflammatory state. </plain></SENT>
</text></p><p><text><SENT sid="26" pm="."><plain>Flagellin that gains access to the cytosol is also a trigger for the NAIP–NLRC4 inflammasome, where flagellin is sensed by the cytosolic receptor, NAIP5/6 and provokes its interaction with the adapter protein, NLRC4 [27,28,29,30,31,32,33,34,35]. </plain></SENT>
<SENT sid="27" pm="."><plain>This cascade triggers inflammasome assembly and subsequent caspase-1 activation [32,34,35,36,37]. </plain></SENT>
<SENT sid="28" pm="."><plain>Activated caspase-1 processes several pro-inflammatory cytokines including pro-IL1β and pro-IL-18, thus promoting secretion of their biologically active forms. </plain></SENT>
</text></p><p><text><SENT sid="29" pm="."><plain>Flagellin has a four-domain structure [14,21,38], wherein domains D0 and D1 are formed by interaction between the N-terminal and C-terminal portions of the protein thus producing a stalk-like structure with a concave surface. </plain></SENT>
<SENT sid="30" pm="."><plain>The central domains D2 and D3 form a cluster emanating at an angle from this stalk (Figure 1). </plain></SENT>
<SENT sid="31" pm="."><plain>The N and C-termini are critical to flagellin polymerization and certain residue stretches are highly conserved among β and γ Proteobacteria, whereas the D2 and D3 domains are highly variable among different bacteria [21,39]. </plain></SENT>
<SENT sid="32" pm="."><plain>Conserved stretches of the D1 domain contains the key residues engaging with TLR5 and remain sequestered from immune selective pressure while flagellin is in a polymerized state [24,40,41,42,43]. </plain></SENT>
<SENT sid="33" pm="."><plain>The C-terminal portion of the D0 domain is also highly conserved and is essential for NAIP-NLRC4 inflammasome triggering [27,32,44]. </plain></SENT>
<SENT sid="34" pm="."><plain>Conversely, the hypervariable region is exposed on the outside surface of the flagellar apparatus and is a dominant target for humoral responses [42,45,46,47]. </plain></SENT>
</text></p><p><text><SENT sid="35" pm="."><plain>Stemming from initial observations of broad and protective immune responses to live attenuated Salmonella oral vaccines [48], it was postulated that such vaccines might prove useful as carriers for heterologous antigens [49,50,51]. </plain></SENT>
<SENT sid="36" pm="."><plain>Thereafter, the insertion of heterologous epitopes into flagellin to produce a combined antigen-adjuvant module was described in seminal work using either live attenuated Salmonella or purified flagellin as the epitope carrier [52,53,54,55,56,57,58,59,60,61]. </plain></SENT>
<SENT sid="37" pm="."><plain>Stemming from these initial observations, additional studies have further defined the mechanisms behind the adjuvant effect of flagellin [21,23] and led to testing of novel vaccine designs in pre-clinical [62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80] and clinical studies [81,82,83,84,85]. </plain></SENT>
<SENT sid="38" pm="."><plain>Some have used flagellin as a stand-alone adjuvant that is concurrently delivered with antigen [86,87,88,89], whereas other studies have demonstrated a distinct advantage to incorporating heterologous epitopes within the structure of flagellin itself at either the N or C-terminus or within the hypervariable region [72,73]. </plain></SENT>
<SENT sid="39" pm="."><plain>Flagellin mediated enhancement of humoral responses appears to require stimulation of TLR5-expressing dendritic cells with subsequent activation of antigen-specific CD4 T-cells [21,23,26,73,86,90,91]. </plain></SENT>
<SENT sid="40" pm="."><plain>The TLR5-MyD88 or NAIP-NLRC4 pathway dependence of these adjuvant effects has clearly been demonstrated [21,23,33,72,91] but some work has raised the possibility that flagellin may also enhance immune responses via alternate mechanisms [92,93,94,95]. </plain></SENT>
</text></p><p><text><SENT sid="41" pm="."><plain>For the majority of licensed vaccines, prevention of infection correlates with the induction of pathogen-specific antibodies [96,97]. </plain></SENT>
<SENT sid="42" pm="."><plain>In the context of viral infection, neutralizing antibodies block interaction of the virus with target receptors on host cells and prevent entry and thus subsequent replication. </plain></SENT>
<SENT sid="43" pm="."><plain>Despite the recent discovery of a great number of potent HIV-1 envelope-specific broadly neutralizing antibodies, an inability to elicit such antibodies through immunization continues to hinder the HIV vaccine discovery enterprise [98,99]. </plain></SENT>
</text></p><p><text><SENT sid="44" pm="."><plain>The HIV gp41 membrane proximal external region (MPER) represents one important but formidable target for HIV-1 vaccine development. </plain></SENT>
<SENT sid="45" pm="."><plain>The MPER is a highly conserved region targeted by broadly neutralizing antibodies (bnAbs) [100]. </plain></SENT>
<SENT sid="46" pm="."><plain>Although such MPER-specific antibodies have been shown to prevent infection through passive immunization [101,102,103], numerous animal studies have failed to elicit robust or sufficiently broad neutralizing antibody responses using a variety of strategies [104,105,106,107,108,109,110,111,112,113,114]. </plain></SENT>
<SENT sid="47" pm="."><plain>Issues hindering the development of gp41 MPER as a vaccine target include poor immunogenicity due in part to steric hindrance and lack of accessibility [100,115], hydrophobicity that renders the MPER prone to aggregation in solution [116], immunodominance of adjacent gp41 regions lacking any neutralizing epitopes [117,118] and the apparent auto-reactivity of MPER-specific bnAbs towards cell membrane lipids [119,120]. </plain></SENT>
</text></p><p><text><SENT sid="48" pm="."><plain>Considering these challenges, we sought to use flagellin as both scaffold and adjuvant for HIV gp41, with the aim of eliciting antibodies to the MPER. </plain></SENT>
<SENT sid="49" pm="."><plain>We chose to pursue a gene-based vaccine approach, aiming to provide future capacity to both develop platforms that could express proteins with mammalian glycosylation and conduct iterative research with different DNA and viral vector platforms, two parameters which will likely be key to developing a protective HIV vaccine. </plain></SENT>
<SENT sid="50" pm="."><plain>We devised a straightforward step-wise approach to select FliC-antigen fusion proteins for gene-based vaccine development. </plain></SENT>
<SENT sid="51" pm="."><plain>Accordingly, we generated plasmid DNA vaccine vectors encoding a variety of FliC-HIV gp41 fusion proteins and screened candidate vaccines based on adequate mammalian cell expression, fusion protein secretion, TLR5 agonist activity and gp41 MPER antigenicity. </plain></SENT>
<SENT sid="52" pm="."><plain>Insertion of a gp41-derived sequence at different positions within FliC led to a broad spectrum of outcomes with regard to secretion and agonist activity. </plain></SENT>
<SENT sid="53" pm="."><plain>Utilizing this multi-modal process, we selected a promising vaccine candidate that fulfilled all our screening criteria. </plain></SENT>
<SENT sid="54" pm="."><plain>We demonstrate that this FliC-HIV gp41 DNA vaccine candidate was highly immunogenic relative to a DNA vaccine encoding gp41 alone, eliciting modest MPER-specific humoral immunogenicity. </plain></SENT>
<SENT sid="55" pm="."><plain>Moreover, the augmented immunogenicity of the vaccine was TLR5-dependant. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec id="sec2-viruses-10-00100"><title><text><SENT sid="56" pm="."><plain>2. </plain></SENT>
<SENT sid="57" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec id="sec2dot1-viruses-10-00100"><title><text><SENT sid="58" pm="."><plain>2.1. </plain></SENT>
<SENT sid="59" pm="."><plain>Construction of FliC and HIV-1 gp41 Expression Vectors </plain></SENT>
</text></title><p><text><SENT sid="60" pm="."><plain>All flagellin (FliC) and gp41 gene constructs described were codon optimized and synthesized using the GENEART platform (http://www.lifetechnologies.com/ca/en/home/life-science/cloning/gene-synthesis/geneart-gene-synthesis/geneoptimizer.html) (Life Technologies, Carlsbad, CA, USA). </plain></SENT>
<SENT sid="61" pm="."><plain>To produce a mammalian cell expressed FliC, we used an amino acid sequence identical to that of Salmonella enterica subsp. enterica serovar Typhi flagellin (GenBank: AAA27067.1). </plain></SENT>
<SENT sid="62" pm="."><plain>Numbering of FliC residues in our constructs was based on a previously established numbering convention [18]. </plain></SENT>
<SENT sid="63" pm="."><plain>We previously described generating a Clade C gp41 ectodomain consensus sequence [121]. </plain></SENT>
<SENT sid="64" pm="."><plain>Based on this sequence we subsequently selected a shorter sequence corresponding to the gp41 ectodomain spanning amino acids 607 to 683 in gp160 (according to HxB2 numbering), herein referred to as gp41607–683 (see Supplementary Methods 1). </plain></SENT>
<SENT sid="65" pm="."><plain>For all gene constructs, a tPA signal sequence [122] was added synthetically to the N-terminus and a GGGS linker and 3XFLAG tag were added to the C-terminus. </plain></SENT>
<SENT sid="66" pm="."><plain>For constructs used to produce coating antigen for antibody binding assays, a Twin-Strep-Tag was also added C-terminal to the 3XFLAG tag. </plain></SENT>
<SENT sid="67" pm="."><plain>Synthesized genes were cloned into the pVAX plasmid using BamHI and NotI enzymes. </plain></SENT>
<SENT sid="68" pm="."><plain>Deletion and point mutants and fusion constructs were generated using the Seamless Cloning Kit (Life Technologies, Carlsbad, CA, USA). </plain></SENT>
<SENT sid="69" pm="."><plain>The following constructs were created: gp41607–671 (lacking the twelve most C-terminal residues making up the MPER), FliC R90D, FliC Δ89–96, FliC Δ174–400, FliC Δ220–320, FliC Δ89–96 Δ174–400, FliC Δ89–96 Δ220–320, gp41607–683 FliC Δ174–400, gp41607–683 FliC Δ220–320, FliC Δ174-[gp41607–683]-400, FliC Δ220-[gp41607–683]-320, FliC gp41607–683, FliC Δ174–400 gp41607–683, FliC Δ220–320 gp41607–683 and FliC Δ89–96 Δ174–400 gp41607–683. </plain></SENT>
<SENT sid="70" pm="."><plain>All plasmid DNA expression vectors used in downstream transfection or vaccination experiments were prepared using a Qiagen EndoFree Plasmid kit (Qiagen, Hamburg, Germany). </plain></SENT>
</text></p></sec><sec id="sec2dot2-viruses-10-00100"><title><text><SENT sid="71" pm="."><plain>2.2. </plain></SENT>
<SENT sid="72" pm="."><plain>Cell Culture </plain></SENT>
</text></title><p><text><SENT sid="73" pm="."><plain>HEK 293T cells (CRL-3216; ATCC, Manassas, VA, USA) and the mouse monocyte/macrophage cell line J774A.1 (TIB-67; ATCC, Manassas, VA, USA) were each cultured in Dulbecco’s Minimal Essential Media (DMEM) supplemented with 10% Fetal Bovine Serum (FBS), 10 mM HEPES, 100 U/mL penicillin and 100 μg/mL streptomycin (all from Corning, Tewksbury, MA, USA). </plain></SENT>
<SENT sid="74" pm="."><plain>The human monocyte cell line, THP-1 (TIB-202; ATCC, Manassas, VA, USA) was cultured in RPMI-1640 and the same supplements as well as 0.05 mM 2-mercaptoethanol (Sigma, St Louis, MO, USA). </plain></SENT>
<SENT sid="75" pm="."><plain>HEK-Blue-hTLR5 cells (Invivogen, San Diego, CA, USA) were cultured in Dulbecco’s Minimal Essential Media (DMEM) supplemented with 10% FBS, 10 mM HEPES, 50 U/mL penicillin, 50 μg/mL streptomycin, 30 μg/mL blasticidin and 100 μg/mL zeocin (the latter two reagents from Invivogen, San Diego, CA, USA). </plain></SENT>
<SENT sid="76" pm="."><plain>All cells were cultured at 37 °C and 5% CO2 in a humidified incubator. </plain></SENT>
</text></p></sec><sec id="sec2dot3-viruses-10-00100"><title><text><SENT sid="77" pm="."><plain>2.3. </plain></SENT>
<SENT sid="78" pm="."><plain>Transfection and Cell Lysate/Supernatant Preparation </plain></SENT>
</text></title><p><text><SENT sid="79" pm="."><plain>HEK 293T cells were seeded at 3 × 106 cells/well in a 6 well plate 24 h prior to transfection. </plain></SENT>
<SENT sid="80" pm="."><plain>JetPEI (Polyplus, Illkirch, France) was used for transient transfection of 293T cells. </plain></SENT>
<SENT sid="81" pm="."><plain>Media was changed 24 h after transfection to DMEM supplemented with 1% FBS but otherwise constituted as above. </plain></SENT>
<SENT sid="82" pm="."><plain>Cell lysates and supernatants were collected 48 h after transfection. </plain></SENT>
<SENT sid="83" pm="."><plain>Cells were washed twice with phosphate-buffered saline (PBS) and spun down at 300 g for 10 min. </plain></SENT>
<SENT sid="84" pm="."><plain>Cells were lysed in NP40 cell lysis buffer (Life Technologies, Carlsbad, CA, USA) containing a protease inhibitor cocktail (Sigma, St Louis, MO, USA). </plain></SENT>
<SENT sid="85" pm="."><plain>Cells supernatants were clarified by centrifugation for 15 min at 16,000 g. Cell lysates and clarified supernatants were stored at −20 °C until analyzed. </plain></SENT>
</text></p></sec><sec id="sec2dot4-viruses-10-00100"><title><text><SENT sid="87" pm="."><plain>2.4. </plain></SENT>
<SENT sid="88" pm="."><plain>SDS-PAGE, Immunoblotting and Deglycosylation Studies </plain></SENT>
</text></title><p><text><SENT sid="89" pm="."><plain>All SDS-PAGE and immunoblotting reagents and devices were from the same manufacturer (Life Technologies, Carlsbad, CA, USA), unless otherwise stated. </plain></SENT>
<SENT sid="90" pm="."><plain>All procedures were carried out as previously described [121]. </plain></SENT>
<SENT sid="91" pm="."><plain>Cell lysates and supernatants were incubated at 70 °C for 10 min after the addition of 4X LDS Loading Buffer and Reducing Agent. </plain></SENT>
<SENT sid="92" pm="."><plain>Samples were run on NuPAGE 4–12% Bis-Tris gels at 150 V under reducing conditions. </plain></SENT>
<SENT sid="93" pm="."><plain>Gels were transferred to PVDF membranes using the iBlot transfer device. </plain></SENT>
<SENT sid="94" pm="."><plain>Membranes were blocked for 20 min in 10% non-fat dry milk dissolved in Tris-buffered saline containing 0.05% Tween (TBS-T). </plain></SENT>
<SENT sid="95" pm="."><plain>Resolved proteins were detected by blotting with a mouse anti-FLAG tag antibody, clone M2 (Sigma, St. Louis, MO, USA) diluted to 0.5 μg/mL in 3% milk TBS-T or a mouse anti-Tubulin antibody, clone B3 (Thermo Scientific, Waltham, MA, USA) diluted to 1:2500 in 1% milk TBS-T. </plain></SENT>
<SENT sid="96" pm="."><plain>A secondary goat anti-mouse IgG antibody conjugated to alkaline phosphatase (AP) was diluted to 1:5000 in TBS-T and used to detect the primary antibody. </plain></SENT>
<SENT sid="97" pm="."><plain>CDP-star substrate was used to generate a chemiluminescent signal, which was detected using X-ray film (VWR, Radnor, PA, USA) and an X-ray imager (Kodak, Rochester, NY, USA). </plain></SENT>
<SENT sid="98" pm="."><plain>In deglycosylation studies, we used PNGase F (NEB, Ipswich, MA, USA) to remove N-glycans from proteins of interest, secreted into cell supernatants. </plain></SENT>
<SENT sid="99" pm="."><plain>Cell supernatants at a volume of 13.5 μL were incubated with 1.5 μL of glycoprotein denaturing buffer (NEB, Ipswich, MA, USA) for 10 min at 99 °C. </plain></SENT>
<SENT sid="100" pm="."><plain>Samples were then treated with 1 μL PNGase F for 1 h at 37 °C in the presence of 2 μL NP-40 and 2 μL G7 buffer (NEB, Ipswich, MA, USA). </plain></SENT>
</text></p></sec><sec id="sec2dot5-viruses-10-00100"><title><text><SENT sid="101" pm="."><plain>2.5. </plain></SENT>
<SENT sid="102" pm="."><plain>Secretion ELISA </plain></SENT>
</text></title><p><text><SENT sid="103" pm="."><plain>Cell supernatants (100 μL per well) were applied to anti-FLAG tag antibody-coated plates (GenScript, Piscataway, NJ, USA) and incubated for 1 h at room temperature (RT). </plain></SENT>
<SENT sid="104" pm="."><plain>Plates were subsequently washed three times with PBS-T, then incubated with a mouse anti-FLAG tag antibody conjugated to horseradish peroxidase (HRP) (Sigma, St. Louis, MO, USA) at a 1:20,000 dilution for 1 h at RT. </plain></SENT>
<SENT sid="105" pm="."><plain>After incubation, plates were washed three times and relative amounts of secreted protein were detected using the QuantaRed substrate system (Thermo Scientific, Waltham, MA, USA). </plain></SENT>
<SENT sid="106" pm="."><plain>Data were collected as relative fluorescence units (RFU) using a fluorescence plate reader with an excitation/emission filter of 544 nm/612 nm. </plain></SENT>
<SENT sid="107" pm="."><plain>The relative level of secreted FLAG-tagged protein determined by this secretion ELISA was used to normalize input for the TLR5 agonist activity and antibody binding assays described below. </plain></SENT>
</text></p></sec><sec id="sec2dot6-viruses-10-00100"><title><text><SENT sid="108" pm="."><plain>2.6. </plain></SENT>
<SENT sid="109" pm="."><plain>TLR5 Agonist Activity Assays </plain></SENT>
</text></title><sec id="sec2dot6dot1-viruses-10-00100"><title><text><SENT sid="110" pm="."><plain>2.6.1. </plain></SENT>
<SENT sid="111" pm="."><plain>HEK-Blue-hTLR5 </plain></SENT>
</text></title><p><text><SENT sid="112" pm="."><plain>A cell suspension of 140,000 cells/mL of HEK-Blue-hTLR5 was prepared and 180 μL was plated in each well of a 96-well plate containing 20 μL of a 1:100 dilution of previously normalized supernatants containing flagellin proteins. </plain></SENT>
<SENT sid="113" pm="."><plain>HEK-Blue-hTLR5 cell suspensions used were produced by scraping and dissociation by gentle pipetting. </plain></SENT>
<SENT sid="114" pm="."><plain>Cell culture supernatants were normalized based on the relative amounts of secreted protein determined by the secretion ELISA (described above). </plain></SENT>
<SENT sid="115" pm="."><plain>Treated HEK-Blue-hTLR5 cells were incubated for 20 h prior to determining the quantity of secreted embryonic alkaline phosphatase (SEAP) released into the supernatant using the QUANTI-Blue colorimetric enzyme assay (Invivogen, San Diego, CA, USA) as per manufacturer’s instructions. </plain></SENT>
<SENT sid="116" pm="."><plain>Briefly, 5 μL of treated HEK-Blue-hTLR5 supernatant from each condition was added to 200 μL of QUANTI-Blue reagent. </plain></SENT>
<SENT sid="117" pm="."><plain>After one hour incubation at 37 °C, SEAP was quantified by measuring absorbance at 655 nm. </plain></SENT>
<SENT sid="118" pm="."><plain>Relative quantities, presented as response ratios, were calculated by dividing the absorbance of each condition by the absorbance of the control condition. </plain></SENT>
</text></p></sec><sec id="sec2dot6dot2-viruses-10-00100"><title><text><SENT sid="119" pm="."><plain>2.6.2. </plain></SENT>
<SENT sid="120" pm="."><plain>Transcriptional Activation of IL-1β in Monocyte/Macrophage Cell Lines </plain></SENT>
</text></title><p><text><SENT sid="121" pm="."><plain>A cell suspension of 140,000 cells/mL of either THP-1 or J774A.1 cells was prepared then 180 μL was transferred to wells of a 96-well plate. </plain></SENT>
<SENT sid="122" pm="."><plain>Subsequently, 20 μL of a 1:100 dilution of previously normalized supernatants containing flagellin proteins was added to each well. </plain></SENT>
<SENT sid="123" pm="."><plain>J774A.1 cell suspensions used were produced by scraping and dissociation by gentle pipetting. </plain></SENT>
<SENT sid="124" pm="."><plain>LPS (Invivogen, San Diego, CA, USA) diluted in culture medium at a final concentration of 1 μg/mL was used as a positive control. </plain></SENT>
<SENT sid="125" pm="."><plain>Empty vector-transfected cell supernatant was used as a negative control. </plain></SENT>
<SENT sid="126" pm="."><plain>Treated cells were incubated for 2 h then harvested and RNA was extracted using an RNeasy mini kit (Qiagen, Valencia, CA, USA) with on-column DNase digestion as per the manufacturer’s instructions. </plain></SENT>
<SENT sid="127" pm="."><plain>Eluted RNA was used in a two-step RT-PCR reaction, utilizing the SuperScript IV First-Strand Synthesis System and Platinum Hot Start PCR Master Mix (both from Life Technologies, Carlsbad, CA, USA) as per the manufacturer’s instructions. </plain></SENT>
<SENT sid="128" pm="."><plain>Random hexamers were used in reverse transcription and the following primers were used for PCR: il1beta forward 5′-TGTAATGAAAGACGGCACACC-3′; il1beta reverse 5′-TCTTCTTTGGGTATTGCTTGG-3′; gapdh forward 5′-AGCTTGTCATCAACGGGAAG-3′; gapdh reverse 5′-TTTGATGTTAGTGGGGTCTCG-3′. </plain></SENT>
<SENT sid="129" pm="."><plain>RT-PCR products underwent agarose gel electrophoresis and were stained with SYBR Safe DNA Gel Stain (Life Technologies, Carlsbad, CA, USA) then visualized with a blue-light transilluminator. </plain></SENT>
</text></p></sec></sec><sec id="sec2dot7-viruses-10-00100"><title><text><SENT sid="130" pm="."><plain>2.7. </plain></SENT>
<SENT sid="131" pm="."><plain>ELISA to Detect Binding by Monoclonal bnAb </plain></SENT>
</text></title><p><text><SENT sid="132" pm="."><plain>To assess bnAb binding to secreted gp41607–683 or FliC gp41607–683 proteins, cell supernatants were diluted in DMEM according to the relative level of gp41 determined by the secretion ELISA as previously described [121], then plated on streptavidin coated plates (Thermo Scientific, Waltham, MA, USA) for 1 h at RT and subsequently washed three times with PBS-T. </plain></SENT>
<SENT sid="133" pm="."><plain>Each gp41 antigen was synthetically linked to a 3XFLAG and Twin-Strep-Tag at its C-terminus. </plain></SENT>
<SENT sid="134" pm="."><plain>The following HIV-1 gp41 monoclonal antibody reagents were generously provided by investigators via the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: 4E10 (from Dr. Hermann Katinger) and 10E8 (from Dr. Mark Connors). </plain></SENT>
<SENT sid="135" pm="."><plain>Each bnAb was diluted to 1 μg/mL in 100 μL of PBS-T containing 5% bovine serum albumin (BSA), then applied to wells and allowed to bind for 1 h at RT. </plain></SENT>
<SENT sid="136" pm="."><plain>Plates were washed three times and bnAb binding was probed using a mouse anti-human IgG AP-conjugated antibody (Life Technologies, Carlsbad, CA, USA) diluted 1:5000 in PBS-T containing 5% BSA for 1 h at RT. </plain></SENT>
<SENT sid="137" pm="."><plain>Plates were then washed three times, AttoPhos fluorescent substrate (Promega, Fitchburg, WI, USA) was applied to wells and the plate was incubated for 15 min at RT. </plain></SENT>
<SENT sid="138" pm="."><plain>Data were collected as relative fluorescence units (RFU) using a fluorescence plate reader with an excitation/emission filter of 485 nm/520 nm. </plain></SENT>
<SENT sid="139" pm="."><plain>Results were normalized to levels of secreted protein captured in each well using an HRP-conjugated anti-FLAG tag antibody and QuantaRed substrate as described above. </plain></SENT>
</text></p></sec><sec id="sec2dot8-viruses-10-00100"><title><text><SENT sid="140" pm="."><plain>2.8. </plain></SENT>
<SENT sid="141" pm="."><plain>Mice and Immunizations </plain></SENT>
</text></title><p><text><SENT sid="142" pm="."><plain>All procedures were approved by the institutional Animal Care Committee of McGill University (Protocol #2012-7237 JGH; first approval date: 01/01/2013). </plain></SENT>
<SENT sid="143" pm="."><plain>Guidelines and regulations established by the Canadian Council on Animal Care were adhered to and all experiments complied with ARRIVE guidelines. </plain></SENT>
<SENT sid="144" pm="."><plain>Six-week-old female BALB/c mice were obtained from Charles River Laboratories (Montréal, QC, Canada) and housed under pathogen-free conditions. </plain></SENT>
<SENT sid="145" pm="."><plain>Mice were injected with 50 μg of DNA in each tibialis anterior muscle (50 μL at a concentration of 1 μg/μL in sterile normal saline) with either empty vector negative control (pVAX) or one of three DNA vaccines (gp41607–683, FliC Δ174–400 gp41607–683 or FliC Δ89–96 Δ174–400 gp41607–683). </plain></SENT>
<SENT sid="146" pm="."><plain>Mice were immunized with DNA vaccines either two or four times, depending on the experiment, at two week intervals. </plain></SENT>
<SENT sid="147" pm="."><plain>Blood was collected 2 weeks after the last immunization. </plain></SENT>
<SENT sid="148" pm="."><plain>Whole blood was allowed to clot for 1 h at room temperature then spun down at 2000 g for 15 min. </plain></SENT>
<SENT sid="149" pm="."><plain>Sera were then collected and stored at −80 °C until analysis. </plain></SENT>
</text></p></sec><sec id="sec2dot9-viruses-10-00100"><title><text><SENT sid="150" pm="."><plain>2.9. </plain></SENT>
<SENT sid="151" pm="."><plain>ELISA to Detect Mouse Anti-gp41 IgG Response </plain></SENT>
</text></title><p><text><SENT sid="152" pm="."><plain>Streptavidin-coated (Roche, Basel, Switzerland) or Strep-Tactin-coated plates (IBA Life Sciences, Goettingen, Germany) were coated with either gp41607–683 or gp41607–671 overnight at 4 °C. </plain></SENT>
<SENT sid="153" pm="."><plain>Each gp41 antigen was synthetically linked to a 3XFLAG and Twin-Strep-Tag at its C-terminus. </plain></SENT>
<SENT sid="154" pm="."><plain>Antigen was coated onto plates from clarified supernatants diluted to a concentration of 2 μg/μL of the protein of interest. </plain></SENT>
<SENT sid="155" pm="."><plain>The concentration was determined by ELISA and a standard of FLAG tag immunoprecipitation-purified gp41 as previously described [121]. </plain></SENT>
<SENT sid="156" pm="."><plain>Coated plates were washed three times with PBS-T containing 0.01% BSA. </plain></SENT>
<SENT sid="157" pm="."><plain>Serum from each mouse was serially diluted up to 1:200 (see Supplementary Methods 2) in PBS-T containing 0.01% BSA, applied to the plates and incubated for 2 h at room temperature. </plain></SENT>
<SENT sid="158" pm="."><plain>For experiments assessing MPER specificity of humoral response, sera from the FliCΔ174–400 gp41607–683 vaccinated group were pooled prior to dilution and processed as described above. </plain></SENT>
<SENT sid="159" pm="."><plain>Plates were washed three times and antibody binding was probed using a goat anti-mouse IgG AP-conjugated antibody (Life Technologies, Carlsbad, CA, USA) diluted to 1:5000 in PBS-T containing 0.01% BSA. </plain></SENT>
<SENT sid="160" pm="."><plain>Plates were incubated for 1 h, then washed three times. </plain></SENT>
<SENT sid="161" pm="."><plain>The bound AP-conjugated secondary antibody was detected using the ELISA Amplification System (Life Technologies, Carlsbad, CA, USA) as per manufacturer’s instruction. </plain></SENT>
<SENT sid="162" pm="."><plain>Plates were read on an ELISA plate reader at an absorbance of 495 nm. </plain></SENT>
<SENT sid="163" pm="."><plain>An independent two sample t-test was used to determine statistical significance between experimental arms. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec id="sec3-viruses-10-00100"><title><text><SENT sid="164" pm="."><plain>3. </plain></SENT>
<SENT sid="165" pm="."><plain>Results </plain></SENT>
</text></title><sec id="sec3dot1-viruses-10-00100"><title><text><SENT sid="166" pm="."><plain>3.1. </plain></SENT>
<SENT sid="167" pm="."><plain>Codon-Optimized Salmonella enterica Subsp. enterica Serovar Typhi FliC Can Be Expressed in and Effectively Secreted from Mammalian Cells </plain></SENT>
</text></title><p><text><SENT sid="168" pm="."><plain>We first set out to determine if the FliC gene could be well expressed and effectively secreted by plasmid DNA vector-transfected cells. </plain></SENT>
<SENT sid="169" pm="."><plain>We produced mammalian codon-optimized FliC and inserted it into a CMV promoter driven expression plasmid (pVAX). </plain></SENT>
<SENT sid="170" pm="."><plain>As the hypervariable region of FliC has been shown to be a dominant antigenic region [42,47] that is not necessary for TLR5 agonist function, we also generated 2 hypervariable region deletion mutants of FliC, one lacking residues 174–400 (FliC Δ174–400) and another lacking residues 220–320 (FliC Δ220–320) (Figure 2A) and inserted them into the same backbone vector. </plain></SENT>
<SENT sid="171" pm="."><plain>Similar deletion mutants have previously been described [42,47]. </plain></SENT>
<SENT sid="172" pm="."><plain>After transfection of 293T cells, we gauged the level of expression and secretion using both immunoblotting and ELISA-based methods. </plain></SENT>
<SENT sid="173" pm="."><plain>We observed robust expression of our three FliC variants in cell lysates (Figure 2B), however we also visualized a ladder of products migrating below the predicted size of protein variants suggesting that a portion of the expressed proteins underwent proteolytic cleavage. </plain></SENT>
<SENT sid="174" pm="."><plain>Moreover, while the predicted molecular weight for full length FliC is approximately 60 kDa, the largest and most abundant protein observed in our lysates migrated at approximately 80 kDa. </plain></SENT>
<SENT sid="175" pm="."><plain>Similar results were observed for our deletion mutants (FliC Δ174–400 and FliC Δ220–320), with the largest band migrating at a higher molecular mass then predicted. </plain></SENT>
<SENT sid="176" pm="."><plain>In corresponding supernatants, protein bands at or above the predicted molecular weight were also observed (Figure 2B). </plain></SENT>
<SENT sid="177" pm="."><plain>These findings suggested that the FliC variant, particularly the secreted forms, had undergone extensive glycosylation. </plain></SENT>
<SENT sid="178" pm="."><plain>Indeed, flagellin is glycosylated in bacterial systems [123]. </plain></SENT>
<SENT sid="179" pm="."><plain>It has also been previously shown that baculovirus encoded FliC undergoes N-linked glycosylation when expressed in insect cells (Spodoptera frugiperda Sf9) [78]. </plain></SENT>
<SENT sid="180" pm="."><plain>In silico analysis revealed that the FliC amino acid sequence we utilized contains at least four asparagine residues predicted to be N-glycosylated (http://www.cbs.dtu.dk/services/NetNGlyc/ and Figure S1). </plain></SENT>
<SENT sid="181" pm="."><plain>To address this possibility, supernatants were treated with PNGase F to remove N-linked glycosylations. </plain></SENT>
<SENT sid="182" pm="."><plain>Treatment with PNGase F resulted in the disappearance of the higher molecular mass proteins and visualization of proteins of the predicted size for all three FliC variants (Figure 2B), thus confirming that FliC is glycosylated when expressed in a mammalian system. </plain></SENT>
<SENT sid="183" pm="."><plain>A shift in molecular weight upon PNGase treatment was also observed in cell lysates for all three proteins (Figure S2). </plain></SENT>
<SENT sid="184" pm="."><plain>Of the three FliC variants, full length FliC appeared to be the most highly expressed and secreted (Figure 2B). </plain></SENT>
<SENT sid="185" pm="."><plain>To better estimate the relative degree of secretion of each variant, an ELISA-based assay was used to measure the FLAG-tagged secreted proteins in culture supernatants. </plain></SENT>
<SENT sid="186" pm="."><plain>All FliC variants were readily detectable, however relative to full length FliC, FliCΔ174–400 and especially FliCΔ220–320 exhibited diminished secretion (Figure 2C). </plain></SENT>
</text></p></sec><sec id="sec3dot2-viruses-10-00100"><title><text><SENT sid="187" pm="."><plain>3.2. </plain></SENT>
<SENT sid="188" pm="."><plain>Mammalian Cell-Expressed and Secreted FliC Retains TLR5 Agonist Activity </plain></SENT>
</text></title><p><text><SENT sid="189" pm="."><plain>Next, we sought to ascertain whether mammalian expressed FliC maintained TLR5 agonist activity. </plain></SENT>
<SENT sid="190" pm="."><plain>To this end, we applied transfected cell culture supernatants containing either full length FliC, FliC Δ174–400 or FliC Δ220–320 to HEK-Blue-hTLR5 cells, a TLR5 agonist activity indicator cell. </plain></SENT>
<SENT sid="191" pm="."><plain>Full length FliC and FliC Δ174–400 demonstrated robust TLR5 agonist activity, however FliC Δ220–320 only elicited a minor response (Figure 2D). </plain></SENT>
</text></p><p><text><SENT sid="192" pm="."><plain>To further confirm that our FliC variants were indeed signaling through TLR5, we sought to modify residues in FliC that are necessary for TLR5 agonist activity. </plain></SENT>
<SENT sid="193" pm="."><plain>Residues 89–96 (QRVRELAV), in the D1 domain of FliC, are required for FliC TLR5 agonist function [41,42]. </plain></SENT>
<SENT sid="194" pm="."><plain>We therefore produced deletion mutants of this region (Δ89–96) in full length FliC, FliC Δ174–400 and FliC Δ220–320 (Figure 3A). </plain></SENT>
<SENT sid="195" pm="."><plain>All Δ89–96 constructs were expressed and secreted to a similar extent as their parent constructs (Figure 3B). </plain></SENT>
<SENT sid="196" pm="."><plain>No TLR5 agonist activity was observed with any construct containing the Δ89–96 deletion as compared to their parental constructs and in fact their responses were no different than that produced by the empty vector control construct (Figure 3C). </plain></SENT>
<SENT sid="197" pm="."><plain>This confirmed that the responses produced by the indicator cell line upon exposure to FliC, FliC Δ174–400 and FliC Δ220–320 were dependent on the TLR5 agonist activity of FliC. </plain></SENT>
</text></p><p><text><SENT sid="198" pm="."><plain>Having confirmed TLR5 agonist activity for our FliC variants using HEK-Blue-hTLR5 cells, we then wished to gauge their capacity for triggering a signaling cascade via TLR5 in a more biologically relevant system. </plain></SENT>
<SENT sid="199" pm="."><plain>To this end we used monocyte cell lines THP-1 (human) and J774A.1 (mouse). </plain></SENT>
<SENT sid="200" pm="."><plain>These cell lines express TLR5 on their surface and engagement of TLR5 by flagellin would activate signaling pathways that would ultimately lead to the transcriptional upregulation of pro-inflammatory cytokines [124,125]. </plain></SENT>
<SENT sid="201" pm="."><plain>Accordingly, we exposed these cells to either full length FliC, FliC Δ89–96 or full-length FliC containing the point mutation R90D (FliC R90D). </plain></SENT>
<SENT sid="202" pm="."><plain>Mutations at position R90 in FliC have been previously shown to diminish or abrogate signaling via mouse or human TLR5, respectively [18,126,127,128]. </plain></SENT>
</text></p><p><text><SENT sid="203" pm="."><plain>Focusing on one such cytokine, IL-1β, we compared the relative abundance of IL-1β transcripts in THP-1 or J774A.1 cells after exposure to either full length FliC, FliC R90D or FliC Δ89–96. </plain></SENT>
<SENT sid="204" pm="."><plain>In parallel, cells were also exposed to either positive or negative control conditions using LPS or supernatant from empty vector-transfected cells, respectively. </plain></SENT>
<SENT sid="205" pm="."><plain>In THP-1 cells, full length FliC and LPS clearly induced IL-1β (Figure 3D). </plain></SENT>
<SENT sid="206" pm="."><plain>FliC R90D and FliC Δ89–96 failed to induce any IL-1β beyond the basal level present in our negative control conditions. </plain></SENT>
<SENT sid="207" pm="."><plain>Results with J774A.1 cells were similar except that FliC R90D retained its ability to induce IL-1β (Figure 3D). </plain></SENT>
<SENT sid="208" pm="."><plain>The difference in intra-species sensitivity to FliC R90 mutant agonist activity was in keeping with previously published work [126,127,128]. </plain></SENT>
<SENT sid="209" pm="."><plain>Overall, these experiments further confirmed that mammalian cell expressed FliC variants can trigger a signaling cascade via TLR5. </plain></SENT>
</text></p></sec><sec id="sec3dot3-viruses-10-00100"><title><text><SENT sid="210" pm="."><plain>3.3. </plain></SENT>
<SENT sid="211" pm="."><plain>Adding gp41 MPER (gp41607–683) to the C Terminus of FliCΔ174–400 Results in a Secreted Protein that Maintains TLR5 Agonist Activity </plain></SENT>
</text></title><p><text><SENT sid="212" pm="."><plain>We next sought to use FliC as both a scaffold and adjuvant for HIV gp41. </plain></SENT>
<SENT sid="213" pm="."><plain>To determine the optimal position to insert gp41 (amino acids 605–683, gp41607–683 herein), we generated eight different constructs wherein gp41607–683 was inserted at the amino- or carboxy-terminus of full length FliC, FliC Δ174–400 and FliC Δ220–320, or alternatively within the remaining hypervariable regions of FliC Δ174–400 and FliC Δ220–320 (Figure 4A). </plain></SENT>
<SENT sid="214" pm="."><plain>All proteins were expressed and secreted to varying degrees as observed by immunoblotting (Figure 4B). </plain></SENT>
<SENT sid="215" pm="."><plain>An ELISA-based assay was once again used to measure the secreted proteins in culture supernatants (Figure 4C). </plain></SENT>
<SENT sid="216" pm="."><plain>The level of secretion varied widely among the different constructs. </plain></SENT>
<SENT sid="217" pm="."><plain>Relative to full length FliC, gp41607–683 insertion at the amino-terminus or within the hypervariable region of FliC Δ174–400 and FliC Δ220–320 variants resulted in an increase in protein secretion (Figure 4C). </plain></SENT>
<SENT sid="218" pm="."><plain>Insertion of gp41607–683 at the carboxy-terminus produced variants that were poorly secreted except for the FliC Δ174–400 variant. </plain></SENT>
</text></p><p><text><SENT sid="219" pm="."><plain>Having gauged the relative secretion levels of our constructs, we next sought to determine if they were able to maintain TLR5 agonist activity. </plain></SENT>
<SENT sid="220" pm="."><plain>Despite their superior propensity for secretion, once normalized for the relative amount of secreted protein, FliC variants with gp41607–683 inserted at the amino-terminus or within the hypervariable regions of FliC Δ174–400 and FliC Δ220–320, manifested weaker TLR5 agonist activity relative to their parent constructs (Figure 4D). </plain></SENT>
<SENT sid="221" pm="."><plain>Instead we observed that insertion of gp41607–683 at the carboxy-terminus preserved TLR5 agonist activity to a greater degree. </plain></SENT>
</text></p></sec><sec id="sec3dot4-viruses-10-00100"><title><text><SENT sid="222" pm="."><plain>3.4. </plain></SENT>
<SENT sid="223" pm="."><plain>Adding gp41 MPER (gp41607–683) to the C Terminus of FliCΔ174–400 Maintains gp41 Antigenicity </plain></SENT>
</text></title><p><text><SENT sid="224" pm="."><plain>As we wished to minimize humoral responses to the FliC hypervariable region, and FliC Δ174–400 produced superior TLR5 agonist activity compared to FliC Δ220–320 (Figure 4D), we chose to pursue the development FliC Δ174–400 gp41607–683 as a DNA vaccine candidate. </plain></SENT>
<SENT sid="225" pm="."><plain>FliC Δ174–400 gp41607–683, FliC Δ174–400 and gp41607–683 were readily detectable in transiently transfected cell lysates and treatment of lysates with PNGase allowed better visualization of each protein (Figure 5A). </plain></SENT>
<SENT sid="226" pm="."><plain>Immunoblotting also allowed us to readily detect secreted proteins although gp41607–683 was only detectable after PNGase treatment (Figure 5A). </plain></SENT>
<SENT sid="227" pm="."><plain>To test if FliC Δ174–400 gp41607–683 maintained gp41 antigenicity, we next sought to ascertain if this protein was bound by the bNAbs 10E8 and 4E10 (Figure 5B) as compared to positive (gp41607–683 in the absence of flagellin) and negative (FliC Δ174–400) control proteins. </plain></SENT>
<SENT sid="228" pm="."><plain>Our experiments revealed that FliC Δ174–400 gp41607–683 was bound by 10E8 and 4E10, albeit to a lesser degree than gp41607–683 (Figure 5C), thus demonstrating preservation of gp41 antigenicity. </plain></SENT>
</text></p></sec><sec id="sec3dot5-viruses-10-00100"><title><text><SENT sid="229" pm="."><plain>3.5. </plain></SENT>
<SENT sid="230" pm="."><plain>FliC Augments gp41607–683 Immunogenicity and Elicits MPER-Specific Humoral Responses </plain></SENT>
</text></title><p><text><SENT sid="231" pm="."><plain>Having determined that FliC Δ174–400 gp41607–683 retained gp41 antigenicity, we then proceeded to gauge the immunogenicity of the expressed protein in the context of a DNA vaccine. </plain></SENT>
<SENT sid="232" pm="."><plain>Mice were immunized with one of three DNA vaccines: pVAX (empty vector control), gp41607–683 or FliC Δ174–400 gp41607–683. </plain></SENT>
<SENT sid="233" pm="."><plain>Mice were immunized on days 0, 14, 28 and 42 and blood was collected 2 weeks post the fourth immunization. </plain></SENT>
<SENT sid="234" pm="."><plain>We then measured gp41-specific IgG responses by ELISA (Figure 6A). </plain></SENT>
<SENT sid="235" pm="."><plain>For the majority of the mice who received FliC Δ174–400 gp41607–683, strong responses were detectable out to a 1/200 dilution of serum (Figure 6A). </plain></SENT>
<SENT sid="236" pm="."><plain>Although the response to FliC Δ174–400 gp41607–683 was modest, it was significantly greater than the response elicited by gp41607–683. </plain></SENT>
<SENT sid="237" pm="."><plain>At this dilution, sera from mice that received gp41607–683 alone manifested responses that were no better than sera from mice who received an empty vector control vaccine (Figure 6A).We then wished to determine if the humoral response generated by FliC Δ174–400 gp41607–683 targeted the C-terminal portion of the MPER or rather residues N-terminal to this region, such as the immunodominant region or the HR2 region [100]. </plain></SENT>
<SENT sid="238" pm="."><plain>We therefore coated our ELISA plate with either gp41607–683 as above or a truncated protein devoid of the majority of the MPER (gp41607–671), then gauged the specificity of pooled sera from our FliC Δ174–400 gp41607–683 vaccinated group. </plain></SENT>
<SENT sid="239" pm="."><plain>The response to the protein containing the MPER was at least five-fold greater in magnitude than that to the protein lacking the MPER (Figure 6B), suggesting that immunization with FliC Δ174–400 gp41 607–683 did indeed elicit an MPER-specific response. </plain></SENT>
<SENT sid="240" pm="."><plain>Taken together our results revealed that FliC, deleted of a large portion of its hypervariable region, augmented humoral responses to gp41607–683 and especially the MPER, when gp41607–683 was incorporated into its C-terminus. </plain></SENT>
</text></p></sec><sec id="sec3dot6-viruses-10-00100"><title><text><SENT sid="241" pm="."><plain>3.6. </plain></SENT>
<SENT sid="242" pm="."><plain>The Adjuvant Effect of FliC is TLR5 Dependent </plain></SENT>
</text></title><p><text><SENT sid="243" pm="."><plain>Our DNA vaccine studies revealed that flagellin did indeed impart an adjuvant effect that enhanced immunogenicity of the gp41 antigen. </plain></SENT>
<SENT sid="244" pm="."><plain>Accordingly, we then wished to gauge the extent to which the adjuvant effect was TLR5 agonist-related or alternatively whether the flagellin scaffold merely acted as a carrier. </plain></SENT>
<SENT sid="245" pm="."><plain>To do so, we immunized mice with one of three vaccines: pVAX (empty vector control), FliC Δ174–400 gp41607–683 or FliC Δ89–96 Δ174–400 gp41607–683. </plain></SENT>
<SENT sid="246" pm="."><plain>In order to minimize any accumulated effect of CD4 helper responses on the humoral response, each group only received a vaccine on days 0 and 14. </plain></SENT>
<SENT sid="247" pm="."><plain>Blood was collected 2 weeks post the second immunization and analyzed for gp41-specific responses by ELISA. </plain></SENT>
<SENT sid="248" pm="."><plain>Relative to FliC Δ174–400 gp41607–683, an inferior response was observed for mice vaccinated with FliC Δ89–96 Δ174–400 gp41607–683 (Figure 7), indicating that the majority of the adjuvant effect of the FliC scaffold was indeed TLR5 dependent. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="sec4-viruses-10-00100"><title><text><SENT sid="249" pm="."><plain>4. </plain></SENT>
<SENT sid="250" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="251" pm="."><plain>The present work demonstrates that codon-optimized Salmonella FliC can be expressed in and effectively secreted from mammalian cells. </plain></SENT>
<SENT sid="252" pm="."><plain>The secreted FliC retains TLR5 agonist activity. </plain></SENT>
<SENT sid="253" pm="."><plain>These findings are in agreement with previous work where a gene-based or viral vector approach was used to express flagellin [127,129,130,131]. </plain></SENT>
</text></p><p><text><SENT sid="254" pm="."><plain>Other investigators have selected a variety of sites for insertion of heterologous into flagellin [23]. </plain></SENT>
<SENT sid="255" pm="."><plain>This has primarily included either the N or C-terminus [63,64,71,72,73,74,75,90] or sites within the hypervariable region [67,69] and in some instances both the hypervariable region and C-terminus were used [62,68,79,84]. </plain></SENT>
<SENT sid="256" pm="."><plain>Although this selection seems at times to be empiric, these sites have historically been selected to both fully expose the inserted epitopes and avoid disrupting conserved flagellin residues, particularly those amino acids shown to be required for TLR5 agonist activity. </plain></SENT>
</text></p><p><text><SENT sid="257" pm="."><plain>We postulated that the location of the inserted heterologous sequence, in our case HIV gp41607–683, would affect the degree of secretion and the TLR5 agonist activity of the resulting fusion protein. </plain></SENT>
<SENT sid="258" pm="."><plain>Indeed, upon testing we noted tremendous variation for different fusion proteins in regard to these two parameters. </plain></SENT>
<SENT sid="259" pm="."><plain>While some fusion proteins were highly secreted, their ability to trigger TLR5 mediated signaling was relatively poor. </plain></SENT>
<SENT sid="260" pm="."><plain>Accordingly, we pursued antigenicity and immunogenicity testing for FliC Δ174–400 HIV gp41607–683, the vaccine candidate that fulfilled both parameters and also lacked immunodominant FliC epitopes [42,45,46,47]. </plain></SENT>
<SENT sid="261" pm="."><plain>We subsequently showed that although FliC Δ174–400 HIV gp41607–683 appeared not to be as readily bound by MPER-specific bnAbs, relative to gp41607–683, it was markedly more immunogenic and appeared to elicit MPER-specific humoral responses. </plain></SENT>
<SENT sid="262" pm="."><plain>Moreover, we showed that the enhancement of immunogenicity was indeed dependent on TLR5 interaction. </plain></SENT>
</text></p><p><text><SENT sid="263" pm="."><plain>We did not pursue immunization experiments in TLR5 knock out mice but instead compared humoral responses between mice that received FliC Δ174–400 HIV gp41607–683 to those that received FliC Δ89–96 Δ174–400 gp41607–683. </plain></SENT>
<SENT sid="264" pm="."><plain>As expected, immunization with the latter vaccine, which lacked residues essential to TLR5 interaction [41,42], produced a humoral response of relatively low magnitude that was only marginally superior to immunization with an empty vector control vaccine. </plain></SENT>
<SENT sid="265" pm="."><plain>Although, we have not definitively excluded a contribution of the NAIP/NLRC4 inflammasome [33] to the adjuvant effect of FliC on humoral responses in the present work, the near complete loss of adjuvant activity with FliC Δ89–96 Δ174–400 gp41607–683 argues against this possibility. </plain></SENT>
</text></p><p><text><SENT sid="266" pm="."><plain>It could be argued that the adjuvant activity we observed was due in part to binding of our expressed fusion protein to TLR5 on dendritic cells or other APC, resulting in facilitated internalization and antigen processing rather than solely initiation of a pro-inflammatory signaling cascade [33,73,90,91,93]. </plain></SENT>
<SENT sid="267" pm="."><plain>Indeed, we cannot exclude the possibility that TLR5-mediated internalization by APC played some role in adjuvant activity or that antigen internalization, dendritic cell maturation and the induction of a pro-inflammatory milieu occurred contemporaneously. </plain></SENT>
</text></p><p><text><SENT sid="268" pm="."><plain>Several observations in our present work generate further questions that we believe should be pursued. </plain></SENT>
<SENT sid="269" pm="."><plain>Two types of post-translational modification were evident in the context of our experiments. </plain></SENT>
<SENT sid="270" pm="."><plain>First, we discovered that vector-expressed FliC was significantly glycosylated. </plain></SENT>
<SENT sid="271" pm="."><plain>Indeed, this was predicted by in silico analysis. </plain></SENT>
<SENT sid="272" pm="."><plain>Moreover, to augment secretion of expressed FliC, all our vectors incorporated a signal peptide fused to the N-terminus of the expressed gene. </plain></SENT>
<SENT sid="273" pm="."><plain>This design would be expected to guide the protein to the secretory pathway where N-glycosylation of FliC might produce progressively oligomeric and branched structures. </plain></SENT>
<SENT sid="274" pm="."><plain>It is unclear if such glycosylation is advantageous. </plain></SENT>
<SENT sid="275" pm="."><plain>Whereas future efforts to purify fusion proteins might be complicated by the presence of a broad spectrum of glycoforms, N-linked glycosylation of FliC might enhance protein stability or perhaps shield and prevent unmasking of sub-dominant B-cell epitopes and thus allow the humoral response to focus on any inserted heterologous epitopes. </plain></SENT>
<SENT sid="276" pm="."><plain>Second, vector-expressed FliC which accumulated intracellularly appeared to undergo extensive proteolytic degradation. </plain></SENT>
<SENT sid="277" pm="."><plain>We did not address the mechanism of degradation in our experiments. </plain></SENT>
<SENT sid="278" pm="."><plain>Proteasomal or lysosomal degradation may have been induced by over-expression and protein misfolding or aggregation [132]. </plain></SENT>
<SENT sid="279" pm="."><plain>It is also interesting to note that the C-terminus of FliC is disordered and appears to be a target of cleavage and subsequent FliC instability [133]. </plain></SENT>
<SENT sid="280" pm="."><plain>Specifically addressing these issues might provide strategies to augment secretion of intact FliC and FliC-antigen fusion proteins. </plain></SENT>
<SENT sid="281" pm="."><plain>Conversely, some propensity for proteolytic cleavage may be advantageous if FliC is taken up by APC and more readily processed for loading onto MHC II. </plain></SENT>
</text></p><p><text><SENT sid="282" pm="."><plain>A major conclusion of the present work is that the insertion site of a heterologous antigen within the FliC scaffold has a marked impact on the resulting fusion protein’s secretion and TLR5 agonist activity. </plain></SENT>
<SENT sid="283" pm="."><plain>It is conceivable that excessive protein aggregation might modulate these parameters. </plain></SENT>
<SENT sid="284" pm="."><plain>Alternatively, interference of the inserted antigen with either TLR5 binding or ligand-receptor dimerization, via inter or intramolecular interaction, might hinder robust signaling. </plain></SENT>
<SENT sid="285" pm="."><plain>Larger inserts might have a more dramatic impact on these parameters. </plain></SENT>
<SENT sid="286" pm="."><plain>Such considerations might influence the desirability of using flagellin as an epitope scaffold rather than a stand-alone co-delivered adjuvant. </plain></SENT>
</text></p><p><text><SENT sid="287" pm="."><plain>We did not specifically address to what extent immune humoral responses were also generated towards the FliC scaffold itself. </plain></SENT>
<SENT sid="288" pm="."><plain>Although the hypervariable region we deleted is known to contain the immunodominant FliC epitopes [42,45,46,47], it is possible that its deletion allowed subdominant B-cell epitopes in other regions to elicit a greater response. </plain></SENT>
<SENT sid="289" pm="."><plain>This may be important to consider with further development, for several reasons. </plain></SENT>
<SENT sid="290" pm="."><plain>First, dominance of B-cell epitopes within FliC might detract to some extent from a robust humoral response to inserted heterologous epitopes. </plain></SENT>
<SENT sid="291" pm="."><plain>Second, the generation of antibodies to regions important for TLR5 binding might neutralize FliC’s potential to act as an adjuvant [42,127]. </plain></SENT>
<SENT sid="292" pm="."><plain>We must also consider that as FliC and gp41 are delivered together in the context of a fusion protein, FliC CD4 epitopes might provide CD4 T-cell help for antibody responses to gp41. </plain></SENT>
<SENT sid="293" pm="."><plain>Further assessment of this possibility should be carried out, both to delineate potential helper epitopes and to gauge the need to introduce heterologous helper epitopes to further enhance the humoral response to gp41. </plain></SENT>
</text></p><p><text><SENT sid="294" pm="."><plain>While we successfully obtained humoral responses to gp41, and to some extent MPER-specificity, the magnitude of responses remained modest. </plain></SENT>
<SENT sid="295" pm="."><plain>Other investigators have also explored using flagellin as an adjuvant to augment responses to the HIV-1 envelope proteins [52,134,135,136] but have not explored flagellin’s potential to augment responses to gp41 MPER. </plain></SENT>
<SENT sid="296" pm="."><plain>Prior to expanding our research to include immunization of rabbits or guinea pigs and evaluation of HIV-1 neutralization capacity, we must both address some of the outstanding questions posed above and devise a regimen to further improve immunogenicity. </plain></SENT>
<SENT sid="297" pm="."><plain>Immunogenicity of our present DNA vaccine, FliC Δ174–400 HIV gp41607–683, would likely be significantly improved by enhanced delivery methods such as in vivo electroporation. </plain></SENT>
<SENT sid="298" pm="."><plain>A prime-boost strategy will also likely be necessary to achieve the desired level of immunogenicity. </plain></SENT>
<SENT sid="299" pm="."><plain>Accordingly, DNA prime-protein boost or DNA prime-viral vector boost regimens should be explored. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="300" pm="."><plain>We are grateful to Mark A. Wainberg for the unwavering support, keen insight and generous mentorship that he provided throughout the course of our work. </plain></SENT>
<SENT sid="302" pm="."><plain>This work was supported by the Canadian Institutes of Health Research (CIHR) and the Canadian HIV Vaccine Initiative (CHVI) through an HIV-1/AIDS Vaccine Discovery and Social Research Team Grant (Principal Investigator: Mark A. Wainberg, Co-Investigator: Gerasimos J. Zaharatos; CIHR Funding Reference Number: THA-118628). </plain></SENT>
<SENT sid="305" pm="."><plain>Luca Melnychuk was a recipient of a Frederick Banting and Charles Best Canada Graduate Scholarship Master’s Award from the CIHR (CIHR Funding Reference Number: GSM-129996). </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="APPENDIX"><app-group><app id="app1-viruses-10-00100"><title>Supplementary Materials</title><p>The following are available online at <uri xlink:href="http://www.mdpi.com/1999-4915/10/3/100/s1">http://www.mdpi.com/1999-4915/10/3/100/s1</uri>, Supplementary Methods 1: HIV-1 gp41 sequence selection, Supplementary Methods 2: End-point titer selection, Figure S1: In silico prediction of N-glycosylation of FliC amino acid residues, Figure S2: Western blot of cell lysates from transiently transfected 293T before and after treatment with PNGase F.</p><supplementary-material content-type="local-data" id="viruses-10-00100-s001"><media xlink:href="viruses-10-00100-s001.zip"><caption><p><text><SENT sid="306" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></app></app-group></SecTag><notes><title>Author Contributions</title><p>Lara Ajamian, Luca Melnychuk and Gerasimos J. Zaharatos designed the experiments and analyzed the data. Lara Ajamian, Luca Melnychuk and Patrick Jean-Pierre performed the experiments. Lara Ajamian and Gerasimos J. Zaharatos wrote the manuscript. Gerasimos J. Zaharatos oversaw and guided all experiments. All authors critically reviewed the manuscript and approved the final version.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors have no conflict of interest to declare.</p></notes><SecTag type="REF"><ref-list><title>References</title><ref id="B1-viruses-10-00100"><text><SENT sid="307" pm="."><plain>1.PlotkinS.A.Vaccines: The fourth centuryClin. </plain></SENT>
<SENT sid="308" pm="."><plain>Vaccine Immunol.2009161709171910.1128/CVI.00290-09<?supplied-pmid 19793898?>19793898 </plain></SENT>
</text></ref><ref id="B2-viruses-10-00100"><text><SENT sid="309" pm="."><plain>2.KoffW.C.BurtonD.R.JohnsonP.R.WalkerB.D.KingC.R.NabelG.J.AhmedR.BhanM.K.PlotkinS.A.Accelerating Next-Generation Vaccine Development for Global Disease PreventionScience2013340123291010.1126/science.1232910<?supplied-pmid 23723240?>23723240 </plain></SENT>
</text></ref><ref id="B3-viruses-10-00100"><text><SENT sid="310" pm="."><plain>3.KoffW.C.A shot at AIDSCurr. </plain></SENT>
<SENT sid="311" pm="."><plain>Opin. </plain></SENT>
<SENT sid="312" pm="."><plain>Biotechnol.20164214715110.1016/j.copbio.2016.03.007<?supplied-pmid 27153215?>27153215 </plain></SENT>
</text></ref><ref id="B4-viruses-10-00100"><text><SENT sid="313" pm="."><plain>4.Amed OuattaraM.B.L.Vaccines Against MalariaClin. </plain></SENT>
<SENT sid="314" pm="."><plain>Infect. </plain></SENT>
<SENT sid="315" pm="."><plain>Dis.20156093093610.1093/cid/ciu954<?supplied-pmid 25452593?>25452593 </plain></SENT>
</text></ref><ref id="B5-viruses-10-00100"><text><SENT sid="316" pm="."><plain>5.OrmeI.M.RobinsonR.T.CooperA.M.The balance between protective and pathogenic immune responses in the TB-infected lungNat. </plain></SENT>
<SENT sid="317" pm="."><plain>Immunol.201416576310.1038/ni.3048<?supplied-pmid 25521685?>25521685 </plain></SENT>
</text></ref><ref id="B6-viruses-10-00100"><text><SENT sid="318" pm="."><plain>6.SmithK.C.OrmeI.M.StarkeJ.R.35—Tuberculosis vaccinesVaccines6th ed.PlotkinS.A.OrensteinW.A.OffitP.A.W.B. </plain></SENT>
<SENT sid="319" pm="."><plain>SaundersLondon, UK2013789811 </plain></SENT>
</text></ref><ref id="B7-viruses-10-00100"><text><SENT sid="320" pm="."><plain>7.LiangT.J.Current progress in development of hepatitis C virus vaccinesNat. </plain></SENT>
<SENT sid="321" pm="."><plain>Med.20131986987810.1038/nm.3183<?supplied-pmid 23836237?>23836237 </plain></SENT>
</text></ref><ref id="B8-viruses-10-00100"><text><SENT sid="322" pm="."><plain>8.AndersenP.KaufmannS.H.E.Novel Vaccination Strategies against TuberculosisCold Spring Harb. </plain></SENT>
<SENT sid="323" pm="."><plain>Perspect. </plain></SENT>
<SENT sid="324" pm="."><plain>Med.20144a01852310.1101/cshperspect.a018523<?supplied-pmid 24890836?>24890836 </plain></SENT>
</text></ref><ref id="B9-viruses-10-00100"><text><SENT sid="325" pm="."><plain>9.ParksC.L.Replication-Competent Viral Vectors for Vaccine DeliveryHuman VaccinesModjarradK.KoffW.C.Academic PressCambridge, MA, USA2017Chapter 22563 </plain></SENT>
</text></ref><ref id="B10-viruses-10-00100"><text><SENT sid="326" pm="."><plain>10.CoffmanR.L.SherA.SederR.A.Vaccine Adjuvants: Putting Innate Immunity to WorkImmunity20103349250310.1016/j.immuni.2010.10.002<?supplied-pmid 21029960?>21029960 </plain></SENT>
</text></ref><ref id="B11-viruses-10-00100"><text><SENT sid="327" pm="."><plain>11.GarçonN.HemS.FriedeM.Evolution of adjuvants across the centuriesVaccines6th ed.ElsevierLondon, UK20135870 </plain></SENT>
</text></ref><ref id="B12-viruses-10-00100"><text><SENT sid="328" pm="."><plain>12.LevitzS.M.GolenbockD.T.Beyond Empiricism: Informing Vaccine Development through Innate Immunity ResearchCell20121481284129210.1016/j.cell.2012.02.012<?supplied-pmid 22424235?>22424235 </plain></SENT>
</text></ref><ref id="B13-viruses-10-00100"><text><SENT sid="329" pm="."><plain>13.MaisonneuveC.BertholetS.PhilpottD.J.De GregorioE.Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvantsProc. </plain></SENT>
<SENT sid="330" pm="."><plain>Natl. </plain></SENT>
<SENT sid="331" pm="."><plain>Acad. </plain></SENT>
<SENT sid="332" pm="."><plain>Sci. </plain></SENT>
<SENT sid="333" pm="."><plain>USA2014111122941229910.1073/pnas.1400478111<?supplied-pmid 25136133?>25136133 </plain></SENT>
</text></ref><ref id="B14-viruses-10-00100"><text><SENT sid="334" pm="."><plain>14.RossezY.WolfsonE.B.HolmesA.GallyD.L.HoldenN.J.Bacterial Flagella: Twist and Stick, or Dodge across the KingdomsPLoS Pathog.201511e100448310.1371/journal.ppat.1004483<?supplied-pmid 25590430?>25590430 </plain></SENT>
</text></ref><ref id="B15-viruses-10-00100"><text><SENT sid="335" pm="."><plain>15.HayashiF.SmithK.D.OzinskyA.HawnT.R.YiE.C.GoodlettD.R.EngJ.K.AkiraS.UnderhillD.M.AderemA.The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5: Article: NatureNature20014101099110310.1038/35074106<?supplied-pmid 11323673?>11323673 </plain></SENT>
</text></ref><ref id="B16-viruses-10-00100"><text><SENT sid="336" pm="."><plain>16.GewirtzA.T.NavasT.A.LyonsS.GodowskiP.J.MadaraJ.L.Cutting edge: Bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expressionJ. </plain></SENT>
<SENT sid="337" pm="."><plain>Immunol.20011671882188510.4049/jimmunol.167.4.1882<?supplied-pmid 11489966?>11489966 </plain></SENT>
</text></ref><ref id="B17-viruses-10-00100"><text><SENT sid="338" pm="."><plain>17.MeansT.K.HayashiF.SmithK.D.AderemA.LusterA.D.The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cellsJ. </plain></SENT>
<SENT sid="339" pm="."><plain>Immunol.20031705165517510.4049/jimmunol.170.10.5165<?supplied-pmid 12734364?>12734364 </plain></SENT>
</text></ref><ref id="B18-viruses-10-00100"><text><SENT sid="340" pm="."><plain>18.SmithK.D.Andersen-NissenE.HayashiF.StrobeK.BergmanM.A.BarrettS.L.R.CooksonB.T.AderemA.Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motilityNat. </plain></SENT>
<SENT sid="341" pm="."><plain>Immunol.200341247125310.1038/ni1011<?supplied-pmid 14625549?>14625549 </plain></SENT>
</text></ref><ref id="B19-viruses-10-00100"><text><SENT sid="342" pm="."><plain>19.MurthyK.G.K.DebA.GoonesekeraS.SzabóC.SalzmanA.L.Identification of conserved domains in Salmonella muenchen flagellin that are essential for its ability to activate TLR5 and to induce an inflammatory response in vitroJ. </plain></SENT>
<SENT sid="343" pm="."><plain>Biol. </plain></SENT>
<SENT sid="344" pm="."><plain>Chem.20042795667567510.1074/jbc.M307759200<?supplied-pmid 14634022?>14634022 </plain></SENT>
</text></ref><ref id="B20-viruses-10-00100"><text><SENT sid="345" pm="."><plain>20.FeuilletV.MedjaneS.MondorI.DemariaO.PagniP.P.GalánJ.E.FlavellR.A.AlexopoulouL.Involvement of Toll-like receptor 5 in the recognition of flagellated bacteriaPNAS2006103124871249210.1073/pnas.0605200103<?supplied-pmid 16891416?>16891416 </plain></SENT>
</text></ref><ref id="B21-viruses-10-00100"><text><SENT sid="346" pm="."><plain>21.HonkoA.N.MizelS.B.Effects of flagellin on innate and adaptive immunityImmunol. </plain></SENT>
<SENT sid="347" pm="."><plain>Res.2005338310110.1385/IR:33:1:08316120974 </plain></SENT>
</text></ref><ref id="B22-viruses-10-00100"><text><SENT sid="348" pm="."><plain>22.Vijay-KumarM.GewirtzA.T.Flagellin: Key target of mucosal innate immunityMucosal Immunol.2009219720510.1038/mi.2009.9<?supplied-pmid 19242410?>19242410 </plain></SENT>
</text></ref><ref id="B23-viruses-10-00100"><text><SENT sid="349" pm="."><plain>23.MizelS.B.BatesJ.T.Flagellin as an adjuvant: Cellular mechanisms and potentialJ. </plain></SENT>
<SENT sid="350" pm="."><plain>Immunol.20101855677568210.4049/jimmunol.1002156<?supplied-pmid 21048152?>21048152 </plain></SENT>
</text></ref><ref id="B24-viruses-10-00100"><text><SENT sid="351" pm="."><plain>24.YoonS.-I.KurnasovO.NatarajanV.HongM.GudkovA.V.OstermanA.L.WilsonI.A.Structural Basis of TLR5-Flagellin Recognition and SignalingScience201233585986410.1126/science.1215584<?supplied-pmid 22344444?>22344444 </plain></SENT>
</text></ref><ref id="B25-viruses-10-00100"><text><SENT sid="352" pm="."><plain>25.LuJ.SunP.D.The Structure of the TLR5-Flagellin Complex: A New Mode of Pathogen Detection, Conserved Receptor Dimerization for SignalingSci. </plain></SENT>
<SENT sid="353" pm="."><plain>Signal.20125pe1110.1126/scisignal.2002963<?supplied-pmid 22720339?>22720339 </plain></SENT>
</text></ref><ref id="B26-viruses-10-00100"><text><SENT sid="354" pm="."><plain>26.DidierlaurentA.FerreroI.OttenL.A.DuboisB.ReinhardtM.CarlsenH.BlomhoffR.AkiraS.KraehenbuhlJ.-P.SirardJ.-C.Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type responseJ. </plain></SENT>
<SENT sid="355" pm="."><plain>Immunol.20041726922693010.4049/jimmunol.172.11.6922<?supplied-pmid 15153511?>15153511 </plain></SENT>
</text></ref><ref id="B27-viruses-10-00100"><text><SENT sid="356" pm="."><plain>27.LightfieldK.L.PerssonJ.BrubakerS.W.WitteC.E.von MoltkeJ.DunipaceE.A.HenryT.SunY.-H.CadoD.DietrichW.F.Critical function for Naip5 in inflammasome activation by a conserved carboxy-terminal domain of flagellinNat. </plain></SENT>
<SENT sid="357" pm="."><plain>Immunol.200891171117810.1038/ni.1646<?supplied-pmid 18724372?>18724372 </plain></SENT>
</text></ref><ref id="B28-viruses-10-00100"><text><SENT sid="358" pm="."><plain>28.KofoedE.M.VanceR.E.Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificityNature201147759259510.1038/nature10394<?supplied-pmid 21874021?>21874021 </plain></SENT>
</text></ref><ref id="B29-viruses-10-00100"><text><SENT sid="359" pm="."><plain>29.KortmannJ.BrubakerS.W.MonackD.M.Cutting Edge: Inflammasome Activation in Primary Human Macrophages Is Dependent on FlagellinJ. </plain></SENT>
<SENT sid="360" pm="."><plain>Immunol.201519581581910.4049/jimmunol.1403100<?supplied-pmid 26109648?>26109648 </plain></SENT>
</text></ref><ref id="B30-viruses-10-00100"><text><SENT sid="361" pm="."><plain>30.RauchI.TenthoreyJ.L.NicholsR.D.Moussawi AlK.KangJ.J.KangC.KazmierczakB.I.VanceR.E.NAIP proteins are required for cytosolic detection of specific bacterial ligands in vivoJ. </plain></SENT>
<SENT sid="362" pm="."><plain>Exp. </plain></SENT>
<SENT sid="363" pm="."><plain>Med.201621365766510.1084/jem.20151809<?supplied-pmid 27045008?>27045008 </plain></SENT>
</text></ref><ref id="B31-viruses-10-00100"><text><SENT sid="364" pm="."><plain>31.ZhaoY.ShiJ.ShiX.WangY.WangF.ShaoF.Genetic functions of the NAIP family of inflammasome receptors for bacterial ligands in miceJ. </plain></SENT>
<SENT sid="365" pm="."><plain>Exp. </plain></SENT>
<SENT sid="366" pm="."><plain>Med.201621364765610.1084/jem.20160006<?supplied-pmid 27114610?>27114610 </plain></SENT>
</text></ref><ref id="B32-viruses-10-00100"><text><SENT sid="367" pm="."><plain>32.ZhaoY.ShaoF.The NAIP–NLRC4 inflammasome in innate immune detection of bacterial flagellin and type III secretion apparatusImmunol. </plain></SENT>
<SENT sid="368" pm="."><plain>Rev.20152658510210.1111/imr.12293<?supplied-pmid 25879286?>25879286 </plain></SENT>
</text></ref><ref id="B33-viruses-10-00100"><text><SENT sid="369" pm="."><plain>33.Vijay-KumarM.CarvalhoF.A.AitkenJ.D.FifadaraN.H.GewirtzA.T.TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellinEur. </plain></SENT>
<SENT sid="370" pm="."><plain>J. </plain></SENT>
<SENT sid="371" pm="."><plain>Immunol.2010403528353410.1002/eji.201040421<?supplied-pmid 21072873?>21072873 </plain></SENT>
</text></ref><ref id="B34-viruses-10-00100"><text><SENT sid="372" pm="."><plain>34.MiaoE.A.Alpuche-ArandaC.M.DorsM.ClarkA.E.BaderM.W.MillerS.I.AderemA.Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1β via IpafNat. </plain></SENT>
<SENT sid="373" pm="."><plain>Immunol.2006756957510.1038/ni1344<?supplied-pmid 16648853?>16648853 </plain></SENT>
</text></ref><ref id="B35-viruses-10-00100"><text><SENT sid="374" pm="."><plain>35.FranchiL.AmerA.Body-MalapelM.KannegantiT.-D.ÖzörenN.JagirdarR.InoharaN.VandenabeeleP.BertinJ.CoyleA.Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1β in salmonella-infected macrophagesNat. </plain></SENT>
<SENT sid="375" pm="."><plain>Immunol.2006757658210.1038/ni1346<?supplied-pmid 16648852?>16648852 </plain></SENT>
</text></ref><ref id="B36-viruses-10-00100"><text><SENT sid="376" pm="."><plain>36.FranchiL.EigenbrodT.Muñoz-PlanilloR.NúñezG.The inflammasome: A caspase-1-activation platform that regulates immune responses and disease pathogenesisNat. </plain></SENT>
<SENT sid="377" pm="."><plain>Immunol.20091024124710.1038/ni.1703<?supplied-pmid 19221555?>19221555 </plain></SENT>
</text></ref><ref id="B37-viruses-10-00100"><text><SENT sid="378" pm="."><plain>37.AachouiY.MiaoE.A.Down with doublespeak: NAIP/NLRC4 inflammasomes get specificJ. </plain></SENT>
<SENT sid="379" pm="."><plain>Exp. </plain></SENT>
<SENT sid="380" pm="."><plain>Med.201621364610.1084/jem.2135insight1<?supplied-pmid 27140198?>27140198 </plain></SENT>
</text></ref><ref id="B38-viruses-10-00100"><text><SENT sid="381" pm="."><plain>38.YonekuraK.Maki-YonekuraS.NambaK.Complete atomic model of the bacterial flagellar filament by electron cryomicroscopyNature200342464365010.1038/nature01830<?supplied-pmid 12904785?>12904785 </plain></SENT>
</text></ref><ref id="B39-viruses-10-00100"><text><SENT sid="382" pm="."><plain>39.BeatsonS.A.MinaminoT.PallenM.J.Variation in bacterial flagellins: From sequence to structureTrends Microbiol.20061415115510.1016/j.tim.2006.02.008<?supplied-pmid 16540320?>16540320 </plain></SENT>
</text></ref><ref id="B40-viruses-10-00100"><text><SENT sid="383" pm="."><plain>40.Eaves-PylesT.D.WongH.R.OdomsK.PylesR.B.Salmonella flagellin-dependent proinflammatory responses are localized to the conserved amino and carboxyl regions of the proteinJ. </plain></SENT>
<SENT sid="384" pm="."><plain>Immunol.20011677009701610.4049/jimmunol.167.12.7009<?supplied-pmid 11739521?>11739521 </plain></SENT>
</text></ref><ref id="B41-viruses-10-00100"><text><SENT sid="385" pm="."><plain>41.Andersen-NissenE.SmithK.D.StrobeK.L.BarrettS.L.R.CooksonB.T.LoganS.M.AderemA.Evasion of Toll-like receptor 5 by flagellated bacteriaProc. </plain></SENT>
<SENT sid="386" pm="."><plain>Natl. </plain></SENT>
<SENT sid="387" pm="."><plain>Acad. </plain></SENT>
<SENT sid="388" pm="."><plain>Sci. </plain></SENT>
<SENT sid="389" pm="."><plain>USA20051029247925210.1073/pnas.0502040102<?supplied-pmid 15956202?>15956202 </plain></SENT>
</text></ref><ref id="B42-viruses-10-00100"><text><SENT sid="390" pm="."><plain>42.NempontC.CayetD.RumboM.BompardC.VilleretV.SirardJ.-C.Deletion of flagellin’s hypervariable region abrogates antibody-mediated neutralization and systemic activation of TLR5-dependent immunityJ. </plain></SENT>
<SENT sid="391" pm="."><plain>Immunol.20081812036204310.4049/jimmunol.181.3.2036<?supplied-pmid 18641341?>18641341 </plain></SENT>
</text></ref><ref id="B43-viruses-10-00100"><text><SENT sid="392" pm="."><plain>43.SongW.S.JeonY.J.NamgungB.HongM.YoonS.-I.A conserved TLR5 binding and activation hot spot on flagellinSci. </plain></SENT>
<SENT sid="393" pm="."><plain>Rep.201774087810.1038/srep40878<?supplied-pmid 28106112?>28106112 </plain></SENT>
</text></ref><ref id="B44-viruses-10-00100"><text><SENT sid="394" pm="."><plain>44.HalffE.F.DiebolderC.A.VersteegM.SchoutenA.BrondijkT.H.C.HuizingaE.G.Formation and structure of a NAIP5-NLRC4 inflammasome induced by direct interactions with conserved N- and C-terminal regions of flagellinJ. </plain></SENT>
<SENT sid="395" pm="."><plain>Biol. </plain></SENT>
<SENT sid="396" pm="."><plain>Chem.2012287384603847210.1074/jbc.M112.393512<?supplied-pmid 23012363?>23012363 </plain></SENT>
</text></ref><ref id="B45-viruses-10-00100"><text><SENT sid="397" pm="."><plain>45.KuwajimaG.Flagellin domain that affects H antigenicity of Escherichia coli K-12J. </plain></SENT>
<SENT sid="398" pm="."><plain>Bacteriol.198817048548810.1128/jb.170.1.485-488.1988<?supplied-pmid 3275631?>3275631 </plain></SENT>
</text></ref><ref id="B46-viruses-10-00100"><text><SENT sid="399" pm="."><plain>46.YoshiokaK.AizawaS.YamaguchiS.Flagellar filament structure and cell motility of Salmonella typhimurium mutants lacking part of the outer domain of flagellinJ. </plain></SENT>
<SENT sid="400" pm="."><plain>Bacteriol.19951771090109310.1128/jb.177.4.1090-1093.1995<?supplied-pmid 7860589?>7860589 </plain></SENT>
</text></ref><ref id="B47-viruses-10-00100"><text><SENT sid="401" pm="."><plain>47.HeX.S.RivkinaM.StockerB.A.RobinsonW.S.Hypervariable region IV of Salmonella gene fliCd encodes a dominant surface epitope and a stabilizing factor for functional flagellaJ. </plain></SENT>
<SENT sid="402" pm="."><plain>Bacteriol.19941762406241410.1128/jb.176.8.2406-2414.1994<?supplied-pmid 7512552?>7512552 </plain></SENT>
</text></ref><ref id="B48-viruses-10-00100"><text><SENT sid="403" pm="."><plain>48.HoisethS.K.StockerB.A.D.Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccinesNature198129123823910.1038/291238a0<?supplied-pmid 7015147?>7015147 </plain></SENT>
</text></ref><ref id="B49-viruses-10-00100"><text><SENT sid="404" pm="."><plain>49.BrownA.HormaecheC.E.de HormaecheR.D.WintherM.DouganG.MaskellD.J.StockerB.A.D.An Attenuated aroA Salmonella typhimurium Vaccine Elicits Humoral and Cellular Immunity to Cloned β-Galactosidase in MiceJ. </plain></SENT>
<SENT sid="405" pm="."><plain>Infect. </plain></SENT>
<SENT sid="406" pm="."><plain>Dis.1987155869210.1093/infdis/155.1.86<?supplied-pmid 3098864?>3098864 </plain></SENT>
</text></ref><ref id="B50-viruses-10-00100"><text><SENT sid="407" pm="."><plain>50.SadoffJ.C.BallouW.R.BaronL.S.MajarianW.R.BreyR.N.HockmeyerW.T.YoungJ.F.CryzS.J.OuJ.LowellG.H.Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malariaScience198824033633810.1126/science.3281260<?supplied-pmid 3281260?>3281260 </plain></SENT>
</text></ref><ref id="B51-viruses-10-00100"><text><SENT sid="408" pm="."><plain>51.ChatfieldS.StrugnellR.DouganG.Live Salmonella as vaccines and carriers of foreign antigenic determinantsVaccine1989749549810.1016/0264-410X(89)90271-52481908 </plain></SENT>
</text></ref><ref id="B52-viruses-10-00100"><text><SENT sid="409" pm="."><plain>52.NewtonS.M.JacobC.O.StockerB.A.Immune response to cholera toxin epitope inserted in Salmonella flagellinScience1989244707210.1126/science.2468182<?supplied-pmid 2468182?>2468182 </plain></SENT>
</text></ref><ref id="B53-viruses-10-00100"><text><SENT sid="410" pm="."><plain>53.WuJ.Y.NewtonS.JuddA.StockerB.RobinsonW.S.Expression of immunogenic epitopes of hepatitis B surface antigen with hybrid flagellin proteins by a vaccine strain of SalmonellaProc. </plain></SENT>
<SENT sid="411" pm="."><plain>Natl. </plain></SENT>
<SENT sid="412" pm="."><plain>Acad. </plain></SENT>
<SENT sid="413" pm="."><plain>Sci. </plain></SENT>
<SENT sid="414" pm="."><plain>USA1989864726473010.1073/pnas.86.12.4726<?supplied-pmid 2471978?>2471978 </plain></SENT>
</text></ref><ref id="B54-viruses-10-00100"><text><SENT sid="415" pm="."><plain>54.NewtonS.M.KotbM.PoirierT.P.StockerB.A.BeacheyE.H.Expression and immunogenicity of a streptococcal M protein epitope inserted in Salmonella flagellinInfect. </plain></SENT>
<SENT sid="416" pm="."><plain>Immun.19915921582165<?supplied-pmid 2037377?>2037377 </plain></SENT>
</text></ref><ref id="B55-viruses-10-00100"><text><SENT sid="417" pm="."><plain>55.CárdenasL.ClementsJ.D.Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigensClin. </plain></SENT>
<SENT sid="418" pm="."><plain>Microbiol. </plain></SENT>
<SENT sid="419" pm="."><plain>Rev.1992532834210.1128/CMR.5.3.328<?supplied-pmid 1498769?>1498769 </plain></SENT>
</text></ref><ref id="B56-viruses-10-00100"><text><SENT sid="420" pm="."><plain>56.McEwenJ.LeviR.HorwitzR.J.ArnonR.Synthetic recombinant vaccine expressing influenza haemagglutinin epitope in Salmonella flagellin leads to partial protection in miceVaccine19921040541110.1016/0264-410X(92)90071-Q1376012 </plain></SENT>
</text></ref><ref id="B57-viruses-10-00100"><text><SENT sid="421" pm="."><plain>57.VermaN.Induction of a cellular immune response to a defined T-cell epitope as an insert in the flagellin of a live vaccine strain of SalmonellaVaccine19951323524410.1016/0264-410X(95)93308-V7543230 </plain></SENT>
</text></ref><ref id="B58-viruses-10-00100"><text><SENT sid="422" pm="."><plain>58.LeviR.Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protectionVaccine199614859210.1016/0264-410X(95)00088-I8821654 </plain></SENT>
</text></ref><ref id="B59-viruses-10-00100"><text><SENT sid="423" pm="."><plain>59.Ben-YedidiaT.ArnonR.Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccineImmunol. </plain></SENT>
<SENT sid="424" pm="."><plain>Lett.19986491510.1016/S0165-2478(98)00073-X9865596 </plain></SENT>
</text></ref><ref id="B60-viruses-10-00100"><text><SENT sid="425" pm="."><plain>60.Ben-YedidiaT.Tarrab-HazdaiR.SchechtmanD.ArnonR.Intranasal administration of synthetic recombinant peptide-based vaccine protects mice from infection by Schistosoma mansoniInfect. </plain></SENT>
<SENT sid="426" pm="."><plain>Immun.19996743604366<?supplied-pmid 10456875?>10456875 </plain></SENT>
</text></ref><ref id="B61-viruses-10-00100"><text><SENT sid="427" pm="."><plain>61.StockerB.A.D.NewtonS.M.C.Immune Responses to Epitopes Inserted in Salmonella FlagellinInt. </plain></SENT>
<SENT sid="428" pm="."><plain>Rev. </plain></SENT>
<SENT sid="429" pm="."><plain>Immunol.20091116717810.3109/08830189409061724 </plain></SENT>
</text></ref><ref id="B62-viruses-10-00100"><text><SENT sid="430" pm="."><plain>62.LiuG.TarbetB.SongL.ReiserovaL.WeaverB.ChenY.LiH.HouF.LiuX.ParentJ.Immunogenicity and Efficacy of Flagellin-Fused Vaccine Candidates Targeting 2009 Pandemic H1N1 Influenza in MicePLoS ONE20116e2092810.1371/journal.pone.0020928<?supplied-pmid 21687743?>21687743 </plain></SENT>
</text></ref><ref id="B63-viruses-10-00100"><text><SENT sid="431" pm="."><plain>63.GhoseC.VerhagenJ.M.ChenX.YuJ.HuangY.ChenesseauO.KellyC.P.HoD.D.Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse model of Clostridium difficile diseaseInfect. </plain></SENT>
<SENT sid="432" pm="."><plain>Immun.20138121902196<?supplied-pmid 23545305?>23545305 </plain></SENT>
</text></ref><ref id="B64-viruses-10-00100"><text><SENT sid="433" pm="."><plain>64.CarapauD.MitchellR.NacerA.ShawA.OthoroC.FrevertU.NardinE.Protective Humoral Immunity Elicited by a Needle-Free Malaria Vaccine Comprised of a Chimeric Plasmodium falciparum Circumsporozoite Protein and a Toll-Like Receptor 5 Agonist, FlagellinInfect. </plain></SENT>
<SENT sid="434" pm="."><plain>Immun.2013814350436210.1128/IAI.00263-13<?supplied-pmid 24042110?>24042110 </plain></SENT>
</text></ref><ref id="B65-viruses-10-00100"><text><SENT sid="435" pm="."><plain>65.LealM.T.A.CamachoA.G.A.TeixeiraL.H.BargieriD.Y.SoaresI.S.TararamC.A.RodriguesM.M.Immunogenicity of recombinant proteins consisting of Plasmodium vivax circumsporozoite protein allelic variant-derived epitopes fused with Salmonella enterica Serovar Typhimurium flagellinClin. </plain></SENT>
<SENT sid="436" pm="."><plain>Vaccine Immunol.2013201418142510.1128/CVI.00312-13<?supplied-pmid 23863502?>23863502 </plain></SENT>
</text></ref><ref id="B66-viruses-10-00100"><text><SENT sid="437" pm="."><plain>66.LiuG.SongL.ReiserovaL.TrivediU.LiH.LiuX.NoahD.HouF.WeaverB.TusseyL.Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infectionsVaccine2012306833683810.1016/j.vaccine.2012.09.013<?supplied-pmid 23000130?>23000130 </plain></SENT>
</text></ref><ref id="B67-viruses-10-00100"><text><SENT sid="438" pm="."><plain>67.BragaC.J.M.MassisL.M.Sbrogio-AlmeidaM.E.AlencarB.C.G.BargieriD.Y.BoscardinS.B.RodriguesM.M.FerreiraL.C.S.CD8+ T cell adjuvant effects of Salmonella FliCd flagellin in live vaccine vectors or as purified proteinVaccine2010281373138210.1016/j.vaccine.2009.11.003<?supplied-pmid 19932669?>19932669 </plain></SENT>
</text></ref><ref id="B68-viruses-10-00100"><text><SENT sid="439" pm="."><plain>68.SongL.ZhangY.YunN.E.PoussardA.L.SmithJ.N.SmithJ.K.BorisevichV.LindeJ.J.ZacksM.A.LiH.Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellinVaccine2009275875588410.1016/j.vaccine.2009.07.060<?supplied-pmid 19654064?>19654064 </plain></SENT>
</text></ref><ref id="B69-viruses-10-00100"><text><SENT sid="440" pm="."><plain>69.MizelS.B.GraffA.H.SriranganathanN.ErvinS.LeesC.J.LivelyM.O.HantganR.R.ThomasM.J.WoodJ.BellB.Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primatesClin. </plain></SENT>
<SENT sid="441" pm="."><plain>Vaccine Immunol.200916212810.1128/CVI.00333-08<?supplied-pmid 18987167?>18987167 </plain></SENT>
</text></ref><ref id="B70-viruses-10-00100"><text><SENT sid="442" pm="."><plain>70.DelaneyK.N.PhippsJ.P.JohnsonJ.B.MizelS.B.A Recombinant Flagellin-Poxvirus Fusion Protein Vaccine Elicits Complement-Dependent Protection Against Respiratory Challenge with Vaccinia Virus in MiceViral Immunol.20102320121010.1089/vim.2009.0107<?supplied-pmid 20374000?>20374000 </plain></SENT>
</text></ref><ref id="B71-viruses-10-00100"><text><SENT sid="443" pm="."><plain>71.HuleattJ.W.NakaarV.DesaiP.HuangY.HewittD.JacobsA.TangJ.McDonaldW.SongL.EvansR.K.Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellinVaccine20082620121410.1016/j.vaccine.2007.10.062<?supplied-pmid 18063235?>18063235 </plain></SENT>
</text></ref><ref id="B72-viruses-10-00100"><text><SENT sid="444" pm="."><plain>72.McDonaldW.F.HuleattJ.W.FoellmerH.G.HewittD.TangJ.DesaiP.PriceA.JacobsA.TakahashiV.N.HuangY.A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunityJ. </plain></SENT>
<SENT sid="445" pm="."><plain>Infect. </plain></SENT>
<SENT sid="446" pm="."><plain>Dis.20071951607161710.1086/517613<?supplied-pmid 17471430?>17471430 </plain></SENT>
</text></ref><ref id="B73-viruses-10-00100"><text><SENT sid="447" pm="."><plain>73.HuleattJ.W.JacobsA.R.TangJ.DesaiP.KoppE.B.HuangY.SongL.NakaarV.PowellT.J.Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunityVaccine20072576377510.1016/j.vaccine.2006.08.013<?supplied-pmid 16968658?>16968658 </plain></SENT>
</text></ref><ref id="B74-viruses-10-00100"><text><SENT sid="448" pm="."><plain>74.SongL.XiongD.HuM.KangX.PanZ.JiaoX.Immunopotentiation of Different Adjuvants on Humoral and Cellular Immune Responses Induced by HA1-2 Subunit Vaccines of H7N9 Influenza in MicePLoS ONE201611e015067810.1371/journal.pone.0150678<?supplied-pmid 26930068?>26930068 </plain></SENT>
</text></ref><ref id="B75-viruses-10-00100"><text><SENT sid="449" pm="."><plain>75.StepanovaL.A.KotlyarovR.Y.KovalevaA.A.PotapchukM.V.KorotkovA.V.SergeevaM.V.KasianenkoM.A.KuprianovV.V.RavinN.V.TsybalovaL.M.Protection against Multiple Influenza A Virus Strains Induced by Candidate Recombinant Vaccine Based on Heterologous M2e Peptides Linked to FlagellinPLoS ONE201510e011952010.1371/journal.pone.0119520<?supplied-pmid 25799221?>25799221 </plain></SENT>
</text></ref><ref id="B76-viruses-10-00100"><text><SENT sid="450" pm="."><plain>76.KalninK.TibbittsT.YanY.StegalkinaS.ShenL.CostaV.SabharwalR.AndersonS.F.DayP.M.ChristensenN.Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypesVaccine2014323540354710.1016/j.vaccine.2014.04.032<?supplied-pmid 24780250?>24780250 </plain></SENT>
</text></ref><ref id="B77-viruses-10-00100"><text><SENT sid="451" pm="."><plain>77.WangB.-Z.GillH.S.KangS.-M.WangL.WangY.-C.VassilievaE.V.CompansR.W.Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligandClin. </plain></SENT>
<SENT sid="452" pm="."><plain>Vaccine Immunol.2012191119112510.1128/CVI.00153-12<?supplied-pmid 22647270?>22647270 </plain></SENT>
</text></ref><ref id="B78-viruses-10-00100"><text><SENT sid="453" pm="."><plain>78.WangB.-Z.QuanF.-S.KangS.-M.BozjaJ.SkountzouI.CompansR.W.Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responsesJ. </plain></SENT>
<SENT sid="454" pm="."><plain>Virol.200882118131182310.1128/JVI.01076-08<?supplied-pmid 18786995?>18786995 </plain></SENT>
</text></ref><ref id="B79-viruses-10-00100"><text><SENT sid="455" pm="."><plain>79.LiuG.SongL.BeasleyD.W.C.PutnakR.ParentJ.MisczakJ.LiH.ReiserovaL.LiuX.TianH.Immunogenicity and Efficacy of Flagellin-Envelope Fusion Dengue Vaccines in Mice and MonkeysClin. </plain></SENT>
<SENT sid="456" pm="."><plain>Vaccine Immunol.20152251652510.1128/CVI.00770-14<?supplied-pmid 25761459?>25761459 </plain></SENT>
</text></ref><ref id="B80-viruses-10-00100"><text><SENT sid="457" pm="."><plain>80.LinK.-H.ChangL.-S.TianC.-Y.YehY.-C.ChenY.-J.ChuangT.-H.LiuS.-J.LengC.-H.Carboxyl-terminal fusion of E7 into Flagellin shifts TLR5 activation to NLRC4/NAIP5 activation and induces TLR5-independent anti-tumor immunitySci. </plain></SENT>
<SENT sid="458" pm="."><plain>Rep.201662419910.1038/srep24199<?supplied-pmid 27063435?>27063435 </plain></SENT>
</text></ref><ref id="B81-viruses-10-00100"><text><SENT sid="459" pm="."><plain>81.TalbotH.K.RockM.T.JohnsonC.TusseyL.KavitaU.ShankerA.ShawA.R.TaylorD.N.Immunopotentiation of Trivalent Influenza Vaccine When Given with VAX102, a Recombinant Influenza M2e Vaccine Fused to the TLR5 Ligand FlagellinPLoS ONE20105e1444210.1371/journal.pone.0014442<?supplied-pmid 21203437?>21203437 </plain></SENT>
</text></ref><ref id="B82-viruses-10-00100"><text><SENT sid="460" pm="."><plain>82.TreanorJ.J.TaylorD.N.TusseyL.HayC.NolanC.FitzgeraldT.LiuG.KavitaU.SongL.DarkI.Safety and immunogenicity of a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125) in healthy young adultsVaccine2010288268827410.1016/j.vaccine.2010.10.009<?supplied-pmid 20969925?>20969925 </plain></SENT>
</text></ref><ref id="B83-viruses-10-00100"><text><SENT sid="461" pm="."><plain>83.TurleyC.B.RuppR.E.JohnsonC.TaylorD.N.WolfsonJ.TusseyL.KavitaU.StanberryL.ShawA.Safety and immunogenicity of a recombinant M2e–flagellin influenza vaccine (STF2.4xM2e) in healthy adultsVaccine2011295145515210.1016/j.vaccine.2011.05.041<?supplied-pmid 21624416?>21624416 </plain></SENT>
</text></ref><ref id="B84-viruses-10-00100"><text><SENT sid="462" pm="."><plain>84.TaylorD.N.TreanorJ.J.SheldonE.A.JohnsonC.UmlaufS.SongL.KavitaU.LiuG.TusseyL.OzerK.Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune responseVaccine2012305761576910.1016/j.vaccine.2012.06.086<?supplied-pmid 22796139?>22796139 </plain></SENT>
</text></ref><ref id="B85-viruses-10-00100"><text><SENT sid="463" pm="."><plain>85.TusseyL.StroutC.DavisM.JohnsonC.LucksingerG.UmlaufS.SongL.LiuG.AbrahamK.WhiteC.J.Phase 1 Safety and Immunogenicity Study of a Quadrivalent Seasonal Flu Vaccine Comprising Recombinant Hemagglutinin-Flagellin Fusion ProteinsOpen Forum Infect. </plain></SENT>
<SENT sid="464" pm="."><plain>Dis.20163ofw01510.1093/ofid/ofw015<?supplied-pmid 26925433?>26925433 </plain></SENT>
</text></ref><ref id="B86-viruses-10-00100"><text><SENT sid="465" pm="."><plain>86.McSorleyS.J.EhstB.D.YuY.GewirtzA.T.Bacterial Flagellin Is an Effective Adjuvant for CD4+ T Cells In VivoJ. </plain></SENT>
<SENT sid="466" pm="."><plain>Immunol.20021693914391910.4049/jimmunol.169.7.3914<?supplied-pmid 12244190?>12244190 </plain></SENT>
</text></ref><ref id="B87-viruses-10-00100"><text><SENT sid="467" pm="."><plain>87.HonkoA.N.SriranganathanN.LeesC.J.MizelS.B.Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestisInfect. </plain></SENT>
<SENT sid="468" pm="."><plain>Immun.2006741113112010.1128/IAI.74.2.1113-1120.2006<?supplied-pmid 16428759?>16428759 </plain></SENT>
</text></ref><ref id="B88-viruses-10-00100"><text><SENT sid="469" pm="."><plain>88.SkountzouI.MartinM.D.P.WangB.YeL.KoutsonanosD.WeldonW.JacobJ.CompansR.W.Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccineVaccine2010284103411210.1016/j.vaccine.2009.07.058<?supplied-pmid 19654062?>19654062 </plain></SENT>
</text></ref><ref id="B89-viruses-10-00100"><text><SENT sid="470" pm="."><plain>89.KimJ.R.HolbrookB.C.HaywardS.L.BlevinsL.K.JorgensenM.J.KockN.D.De ParisK.D’AgostinoR.B.Jr.AycockS.T.MizelS.B.ParksG.D.Alexander-MillerM.A.Inclusion of Flagellin during Vaccination against Influenza Enhances Recall Responses in Nonhuman Primate NeonatesJ. </plain></SENT>
<SENT sid="471" pm="."><plain>Virol.2015897291730310.1128/JVI.00549-15<?supplied-pmid 25948746?>25948746 </plain></SENT>
</text></ref><ref id="B90-viruses-10-00100"><text><SENT sid="472" pm="."><plain>90.CuadrosC.Lopez-HernandezF.J.DominguezA.L.McClellandM.LustgartenJ.Flagellin fusion proteins as adjuvants or vaccines induce specific immune responsesInfect. </plain></SENT>
<SENT sid="473" pm="."><plain>Immun.2004722810281610.1128/IAI.72.5.2810-2816.2004<?supplied-pmid 15102791?>15102791 </plain></SENT>
</text></ref><ref id="B91-viruses-10-00100"><text><SENT sid="474" pm="."><plain>91.BatesJ.T.UematsuS.AkiraS.MizelS.B.Direct stimulation of tlr5+/+ CD11c+ cells is necessary for the adjuvant activity of flagellinJ. </plain></SENT>
<SENT sid="475" pm="."><plain>Immunol.20091827539754710.4049/jimmunol.0804225<?supplied-pmid 19494277?>19494277 </plain></SENT>
</text></ref><ref id="B92-viruses-10-00100"><text><SENT sid="476" pm="."><plain>92.SandersC.J.FranchiL.YarovinskyF.UematsuS.AkiraS.NúñezG.GewirtzA.T.Induction of adaptive immunity by flagellin does not require robust activation of innate immunityEur. </plain></SENT>
<SENT sid="477" pm="."><plain>J. </plain></SENT>
<SENT sid="478" pm="."><plain>Immunol.20093935937110.1002/eji.200838804<?supplied-pmid 19152336?>19152336 </plain></SENT>
</text></ref><ref id="B93-viruses-10-00100"><text><SENT sid="479" pm="."><plain>93.LetranS.E.LeeS.J.AtifS.M.UematsuS.AkiraS.McSorleyS.J.TLR5 functions as an endocytic receptor to enhance flagellin-specific adaptive immunityEur. </plain></SENT>
<SENT sid="480" pm="."><plain>J. </plain></SENT>
<SENT sid="481" pm="."><plain>Immunol.201141293810.1002/eji.201040717<?supplied-pmid 21182074?>21182074 </plain></SENT>
</text></ref><ref id="B94-viruses-10-00100"><text><SENT sid="482" pm="."><plain>94.BatesJ.T.GraffA.H.PhippsJ.P.GraysonJ.M.MizelS.B.Enhanced antigen processing of flagellin fusion proteins promotes the antigen-specific CD8+ T cell response independently of TLR5 and MyDJ. </plain></SENT>
<SENT sid="483" pm="."><plain>Immunol.20111866255626210.4049/jimmunol.1001855<?supplied-pmid 21515787?>21515787 </plain></SENT>
</text></ref><ref id="B95-viruses-10-00100"><text><SENT sid="484" pm="."><plain>95.López-YglesiasA.H.ZhaoX.QuarlesE.K.LaiM.A.VandenBosT.StrongR.K.SmithK.D.Flagellin induces antibody responses through a TLR5- and inflammasome-independent pathwayJ. </plain></SENT>
<SENT sid="485" pm="."><plain>Immunol.20141921587159610.4049/jimmunol.1301893<?supplied-pmid 24442437?>24442437 </plain></SENT>
</text></ref><ref id="B96-viruses-10-00100"><text><SENT sid="486" pm="."><plain>96.PlotkinS.A.Vaccines: Correlates of vaccine-induced immunityClin. </plain></SENT>
<SENT sid="487" pm="."><plain>Infect. </plain></SENT>
<SENT sid="488" pm="."><plain>Dis.20084740140910.1086/589862<?supplied-pmid 18558875?>18558875 </plain></SENT>
</text></ref><ref id="B97-viruses-10-00100"><text><SENT sid="489" pm="."><plain>97.PlotkinS.A.Correlates of protection induced by vaccinationClin. </plain></SENT>
<SENT sid="490" pm="."><plain>Vaccine Immunol.2010171055106510.1128/CVI.00131-10<?supplied-pmid 20463105?>20463105 </plain></SENT>
</text></ref><ref id="B98-viruses-10-00100"><text><SENT sid="491" pm="."><plain>98.BurtonD.R.HangartnerL.Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine DesignAnnu. </plain></SENT>
<SENT sid="492" pm="."><plain>Rev. </plain></SENT>
<SENT sid="493" pm="."><plain>Immunol.20163463565910.1146/annurev-immunol-041015-055515<?supplied-pmid 27168247?>27168247 </plain></SENT>
</text></ref><ref id="B99-viruses-10-00100"><text><SENT sid="494" pm="."><plain>99.SadanandS.SuscovichT.J.AlterG.Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine DesignAnnu. </plain></SENT>
<SENT sid="495" pm="."><plain>Rev. </plain></SENT>
<SENT sid="496" pm="."><plain>Med.20166718520010.1146/annurev-med-091014-090749<?supplied-pmid 26565674?>26565674 </plain></SENT>
</text></ref><ref id="B100-viruses-10-00100"><text><SENT sid="497" pm="."><plain>100.MonteroM.van HoutenN.E.WangX.ScottJ.K.The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: Dominant site of antibody neutralization and target for vaccine designMicrobiol. </plain></SENT>
<SENT sid="498" pm="."><plain>Mol. </plain></SENT>
<SENT sid="499" pm="."><plain>Biol. </plain></SENT>
<SENT sid="500" pm="."><plain>Rev.2008725484table of contents10.1128/MMBR.00020-07<?supplied-pmid 18322034?>18322034 </plain></SENT>
</text></ref><ref id="B101-viruses-10-00100"><text><SENT sid="501" pm="."><plain>101.HessellA.J.RakaszE.G.TehraniD.M.HuberM.WeisgrauK.L.LanducciG.ForthalD.N.KoffW.C.PoignardP.WatkinsD.I.Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-LJ. </plain></SENT>
<SENT sid="502" pm="."><plain>Virol.2010841302131310.1128/JVI.01272-09<?supplied-pmid 19906907?>19906907 </plain></SENT>
</text></ref><ref id="B102-viruses-10-00100"><text><SENT sid="503" pm="."><plain>102.PeguA.YangZ.-Y.BoyingtonJ.C.WuL.KoS.-Y.SchmidtS.D.McKeeK.KongW.-P.ShiW.ChenX.Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptorSci. </plain></SENT>
<SENT sid="504" pm="."><plain>Transl. </plain></SENT>
<SENT sid="505" pm="."><plain>Med.20146243ra8810.1126/scitranslmed.3008992<?supplied-pmid 24990883?>24990883 </plain></SENT>
</text></ref><ref id="B103-viruses-10-00100"><text><SENT sid="506" pm="."><plain>103.PeguA.HessellA.J.MascolaJ.R.HaigwoodN.L.Use of broadly neutralizing antibodies for HIV-1 preventionImmunol. </plain></SENT>
<SENT sid="507" pm="."><plain>Rev.201727529631210.1111/imr.12511<?supplied-pmid 28133803?>28133803 </plain></SENT>
</text></ref><ref id="B104-viruses-10-00100"><text><SENT sid="508" pm="."><plain>104.PhogatS.SvehlaK.TangM.SpadacciniA.MullerJ.MascolaJ.BerkowerI.WyattR.Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particlesVirology2008373728410.1016/j.virol.2007.11.005<?supplied-pmid 18155743?>18155743 </plain></SENT>
</text></ref><ref id="B105-viruses-10-00100"><text><SENT sid="509" pm="."><plain>105.VendittoV.J.WieczorekL.MolnarS.TequeF.LanducciG.WatsonD.S.ForthalD.PolonisV.R.LevyJ.A.SzokaF.C.Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbitsClin. </plain></SENT>
<SENT sid="510" pm="."><plain>Vaccine Immunol.2014211086109310.1128/CVI.00320-14<?supplied-pmid 24872518?>24872518 </plain></SENT>
</text></ref><ref id="B106-viruses-10-00100"><text><SENT sid="511" pm="."><plain>106.DennisonS.M.SutherlandL.L.JaegerF.H.AnastiK.M.ParksR.StewartS.BowmanC.XiaS.-M.ZhangR.ShenX.Induction of Antibodies in Rhesus Macaques That Recognize a Fusion-Intermediate Conformation of HIV-1 gpPLoS ONE20116e2782410.1371/journal.pone.0027824<?supplied-pmid 22140469?>22140469 </plain></SENT>
</text></ref><ref id="B107-viruses-10-00100"><text><SENT sid="512" pm="."><plain>107.StraszN.MorozovV.A.KreutzbergerJ.KellerM.EschrichtM.DennerJ.Immunization with Hybrid Proteins Containing the Membrane Proximal External Region of HIV-1AIDS Res. </plain></SENT>
<SENT sid="513" pm="."><plain>Hum. </plain></SENT>
<SENT sid="514" pm="."><plain>Retrovir.20143049850810.1089/aid.2013.0191<?supplied-pmid 24392780?>24392780 </plain></SENT>
</text></ref><ref id="B108-viruses-10-00100"><text><SENT sid="515" pm="."><plain>108.YeL.WenZ.DongK.WangX.BuZ.ZhangH.CompansR.W.YangC.Induction of HIV Neutralizing Antibodies against the MPER of the HIV Envelope Protein by HA/gp41 Chimeric Protein-Based DNA and VLP VaccinesPLoS ONE20116e1481310.1371/journal.pone.0014813<?supplied-pmid 21625584?>21625584 </plain></SENT>
</text></ref><ref id="B109-viruses-10-00100"><text><SENT sid="516" pm="."><plain>109.VendittoV.J.WatsonD.S.MotionM.MontefioriD.SzokaF.C.Jr.Rational Design of Membrane Proximal External Region Lipopeptides Containing Chemical Modifications for HIV-1 VaccinationClin. </plain></SENT>
<SENT sid="517" pm="."><plain>Vaccine Immunol.201320394510.1128/CVI.00615-12<?supplied-pmid 23114698?>23114698 </plain></SENT>
</text></ref><ref id="B110-viruses-10-00100"><text><SENT sid="518" pm="."><plain>110.JainS.PatrickA.J.RosenthalK.L.Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimenVaccine2010287070708010.1016/j.vaccine.2010.08.009<?supplied-pmid 20723627?>20723627 </plain></SENT>
</text></ref><ref id="B111-viruses-10-00100"><text><SENT sid="519" pm="."><plain>111.ZhaiY.ZhongZ.ZariffardM.SpearG.T.QiaoL.Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodiesVaccine2013315422542910.1016/j.vaccine.2013.09.003<?supplied-pmid 24055348?>24055348 </plain></SENT>
</text></ref><ref id="B112-viruses-10-00100"><text><SENT sid="520" pm="."><plain>112.YiG.LapelosaM.BradleyR.MarianoT.M.DietzD.E.HughesS.WrinT.PetropoulosC.GallicchioE.LevyR.M.Chimeric Rhinoviruses Displaying MPER Epitopes Elicit Anti-HIV Neutralizing ResponsesPLoS ONE20138e7220510.1371/annotation/57fc0148-19fe-4b8b-b2f4-bb5f60baa971<?supplied-pmid 24116242?>24039745 </plain></SENT>
</text></ref><ref id="B113-viruses-10-00100"><text><SENT sid="521" pm="."><plain>113.BoehmeK.W.IkizlerM.IskarpatyotiJ.A.WetzelJ.D.WillisJ.CroweJ.E.LaBrancheC.C.MontefioriD.C.WilsonG.J.DermodyT.S.Engineering Recombinant Reoviruses To Display gp41 Membrane-Proximal External-Region Epitopes from HIV-1mSphere20161e00086-1610.1128/mSphere.00086-16<?supplied-pmid 27303748?>27303748 </plain></SENT>
</text></ref><ref id="B114-viruses-10-00100"><text><SENT sid="522" pm="."><plain>114.Molinos-AlbertL.M.BilbaoE.AgullóL.MarfilS.GarcíaE.de ConcepciónM.L.R.L.Izquierdo-UserosN.VilaplanaC.Nieto-GaraiJ.A.ContrerasF.X.Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motifSci. </plain></SENT>
<SENT sid="523" pm="."><plain>Rep.201774080010.1038/srep40800<?supplied-pmid 28084464?>28084464 </plain></SENT>
</text></ref><ref id="B115-viruses-10-00100"><text><SENT sid="524" pm="."><plain>115.KimM.SongL.MoonJ.SunZ.-Y.J.BershteynA.HansonM.CainD.GokaS.KelsoeG.WagnerG.Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistryJ. </plain></SENT>
<SENT sid="525" pm="."><plain>Biol. </plain></SENT>
<SENT sid="526" pm="."><plain>Chem.2013288318883190110.1074/jbc.M113.494609<?supplied-pmid 24047898?>24047898 </plain></SENT>
</text></ref><ref id="B116-viruses-10-00100"><text><SENT sid="527" pm="."><plain>116.ScholzC.SchaarschmidtP.EngelA.M.AndresH.SchmittU.FaatzE.BalbachJ.SchmidF.X.Functional Solubilization of Aggregation-prone HIV Envelope Proteins by Covalent Fusion with Chaperone ModulesJ. </plain></SENT>
<SENT sid="528" pm="."><plain>Mol. </plain></SENT>
<SENT sid="529" pm="."><plain>Biol.20053451229124110.1016/j.jmb.2004.10.091<?supplied-pmid 15644217?>15644217 </plain></SENT>
</text></ref><ref id="B117-viruses-10-00100"><text><SENT sid="530" pm="."><plain>117.Enshell-SeijffersD.SmelyanskiL.VardinonN.YustI.GershoniJ.M.Dissection of the humoral immune response toward an immunodominant epitope of HIV: A model for the analysis of antibody diversity in HIV+ individualsFASEB J.2001152112212010.1096/fj.00-0898com<?supplied-pmid 11641237?>11641237 </plain></SENT>
</text></ref><ref id="B118-viruses-10-00100"><text><SENT sid="531" pm="."><plain>118.Molinos-AlbertL.M.CarrilloJ.CurriuM.de la ConcepciónM.L.R.MarfilS.GarcíaE.ClotetB.BlancoJ.Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individualsRetrovirology2014114410.1186/1742-4690-11-44<?supplied-pmid 24909946?>24909946 </plain></SENT>
</text></ref><ref id="B119-viruses-10-00100"><text><SENT sid="532" pm="."><plain>119.HaynesB.F.FlemingJ.ClairE.W.S.KatingerH.StieglerG.KunertR.RobinsonJ.ScearceR.M.PlonkK.StaatsH.F.Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 AntibodiesScience20053081906190810.1126/science.1111781<?supplied-pmid 15860590?>15860590 </plain></SENT>
</text></ref><ref id="B120-viruses-10-00100"><text><SENT sid="533" pm="."><plain>120.ChenJ.FreyG.PengH.Rits-VollochS.GarrityJ.SeamanM.S.ChenB.Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41J. </plain></SENT>
<SENT sid="534" pm="."><plain>Virol.2014881249125810.1128/JVI.02664-13<?supplied-pmid 24227838?>24227838 </plain></SENT>
</text></ref><ref id="B121-viruses-10-00100"><text><SENT sid="535" pm="."><plain>121.MelnychukL.AjamianL.Jean-PierreP.LiangJ.GheorgheR.WainbergM.A.ZaharatosG.J.Development of a DNA vaccine expressing a secreted HIV-1 gp41 ectodomain that includes the membrane-proximal external regionVaccine2017352736274410.1016/j.vaccine.2017.03.039<?supplied-pmid 28392143?>28392143 </plain></SENT>
</text></ref><ref id="B122-viruses-10-00100"><text><SENT sid="536" pm="."><plain>122.LiZ.HowardA.KelleyC.DeloguG.CollinsF.MorrisS.Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequencesInfect. </plain></SENT>
<SENT sid="537" pm="."><plain>Immun.19996747804786<?supplied-pmid 10456931?>10456931 </plain></SENT>
</text></ref><ref id="B123-viruses-10-00100"><text><SENT sid="538" pm="."><plain>123.LoganS.M.Flagellar glycosylation—A new component of the motility repertoire?Microbiology20061521249126210.1099/mic.0.28735-0<?supplied-pmid 16622043?>16622043 </plain></SENT>
</text></ref><ref id="B124-viruses-10-00100"><text><SENT sid="539" pm="."><plain>124.KawaiT.AkiraS.Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and ImmunityImmunity20113463765010.1016/j.immuni.2011.05.006<?supplied-pmid 21616434?>21616434 </plain></SENT>
</text></ref><ref id="B125-viruses-10-00100"><text><SENT sid="540" pm="."><plain>125.PandeyS.KawaiT.AkiraS.Microbial sensing by Toll-like receptors and intracellular nucleic acid sensorsCold Spring Harb. </plain></SENT>
<SENT sid="541" pm="."><plain>Perspect. </plain></SENT>
<SENT sid="542" pm="."><plain>Biol.20157a01624610.1101/cshperspect.a016246<?supplied-pmid 25301932?>25301932 </plain></SENT>
</text></ref><ref id="B126-viruses-10-00100"><text><SENT sid="543" pm="."><plain>126.Andersen-NissenE.SmithK.D.BonneauR.StrongR.K.AderemA.A conserved surface on Toll-like receptor 5 recognizes bacterial flagellinJ. </plain></SENT>
<SENT sid="544" pm="."><plain>Exp. </plain></SENT>
<SENT sid="545" pm="."><plain>Med.200720439340310.1084/jem.20061400<?supplied-pmid 17283206?>17283206 </plain></SENT>
</text></ref><ref id="B127-viruses-10-00100"><text><SENT sid="546" pm="."><plain>127.SahaS.TakeshitaF.MatsudaT.JounaiN.KobiyamaK.MatsumotoT.SasakiS.YoshidaA.XinK.-Q.KlinmanD.M.Blocking of the TLR5 activation domain hampers protective potential of flagellin DNA vaccineJ. </plain></SENT>
<SENT sid="547" pm="."><plain>Immunol.20071791147115410.4049/jimmunol.179.2.1147<?supplied-pmid 17617608?>17617608 </plain></SENT>
</text></ref><ref id="B128-viruses-10-00100"><text><SENT sid="548" pm="."><plain>128.ForstneričV.Ivičak-KocjanK.LjubetičA.JeralaR.BenčinaM.Distinctive Recognition of Flagellin by Human and Mouse Toll-Like ReceptorPLoS ONE201611e015889427391968 </plain></SENT>
</text></ref><ref id="B129-viruses-10-00100"><text><SENT sid="549" pm="."><plain>129.AhmedM.PuckettS.ArimilliS.BraxtonC.L.MizelS.B.LylesD.S.Stimulation of human dendritic cells by wild-type and M protein mutant vesicular stomatitis viruses engineered to express bacterial flagellinJ. </plain></SENT>
<SENT sid="550" pm="."><plain>Virol.201084120931209810.1128/JVI.00406-10<?supplied-pmid 20844045?>20844045 </plain></SENT>
</text></ref><ref id="B130-viruses-10-00100"><text><SENT sid="551" pm="."><plain>130.KnudsenM.L.JohanssonD.X.KosticL.NordströmE.K.L.TegerstedtK.PasettoA.ApplequistS.E.LjungbergK.SirardJ.-C.LiljeströmP.The Adjuvant Activity of Alphavirus Replicons Is Enhanced by Incorporating the Microbial Molecule Flagellin into the RepliconPLoS ONE20138e6596410.1371/journal.pone.0065964<?supplied-pmid 23785460?>23785460 </plain></SENT>
</text></ref><ref id="B131-viruses-10-00100"><text><SENT sid="552" pm="."><plain>131.RadyH.F.DaiG.HuangW.ShellitoJ.E.RamsayA.J.Flagellin Encoded in Gene-Based Vector Vaccines Is a Route-Dependent Immune AdjuvantPLoS ONE201611e014870110.1371/journal.pone.0148701<?supplied-pmid 26844553?>26844553 </plain></SENT>
</text></ref><ref id="B132-viruses-10-00100"><text><SENT sid="553" pm="."><plain>132.DikicI.Proteasomal and Autophagic Degradation SystemsAnnu. </plain></SENT>
<SENT sid="554" pm="."><plain>Rev. </plain></SENT>
<SENT sid="555" pm="."><plain>Biochem.20178619322410.1146/annurev-biochem-061516-044908<?supplied-pmid 28460188?>28460188 </plain></SENT>
</text></ref><ref id="B133-viruses-10-00100"><text><SENT sid="556" pm="."><plain>133.VondervisztF.KantoS.AizawaS.NambaK.Terminal regions of flagellin are disordered in solutionJ. </plain></SENT>
<SENT sid="557" pm="."><plain>Mol. </plain></SENT>
<SENT sid="558" pm="."><plain>Biol.198920912713310.1016/0022-2836(89)90176-92810365 </plain></SENT>
</text></ref><ref id="B134-viruses-10-00100"><text><SENT sid="559" pm="."><plain>134.NewtonS.M.C.JoysT.M.AndersonS.A.KennedyR.C.HoviM.E.StockerB.A.D.Expression and immunogenicity of an 18-residue epitope of HIV1 gp41 inserted in the flagellar protein of a Salmonella live vaccineRes. </plain></SENT>
<SENT sid="560" pm="."><plain>Microbiol.199514620321610.1016/0923-2508(96)80276-27569315 </plain></SENT>
</text></ref><ref id="B135-viruses-10-00100"><text><SENT sid="561" pm="."><plain>135.CattozzoE.M.StockerB.A.D.RadaelliA.De Giuli MorghenC.TognonM.Expression and immunogenicity of V3 loop epitopes of HIV-1, isolates SC and WMJ2, inserted in Salmonella flagellinJ. </plain></SENT>
<SENT sid="562" pm="."><plain>Biotechnol.19975619120310.1016/S0168-1656(97)00117-X9304878 </plain></SENT>
</text></ref><ref id="B136-viruses-10-00100"><text><SENT sid="563" pm="."><plain>136.VassilievaE.V.WangB.-Z.VzorovA.N.WangL.WangY.-C.BozjaJ.XuR.CompansR.W.Enhanced Mucosal Immune Responses to HIV Virus-Like Particles Containing a Membrane-Anchored AdjuvantmBio20102e00328-1010.1128/mBio.00328-10<?supplied-pmid 21325038?>21325038 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="FIG"><fig id="viruses-10-00100-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p><text><SENT sid="564" pm="."><plain>Domain structure of full-length flagellin. </plain></SENT>
<SENT sid="565" pm="."><plain>Image derived from PDB ID: 1UCU [38] visualized with iCn3D (https://www.ncbi.nlm.nih.gov/Structure/icn3d/full.html) and modified to indicate D0, D1, D2 and D3 domains. </plain></SENT>
<SENT sid="566" pm="."><plain>Residues 89–96 (QRVRELAV) in the D1 domain are encircled by a red dashed line. </plain></SENT>
</text></p></caption><graphic xlink:href="viruses-10-00100-g001"/></fig></SecTag><SecTag type="FIG"><fig id="viruses-10-00100-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p><text><SENT sid="567" pm="."><plain>FliC constructs expressed in a mammalian system are secreted and maintain Toll-like receptor 5 (TLR5) agonist activity. </plain></SENT>
<SENT sid="568" pm="."><plain>(A) Schematic representation of flagellin (FliC) constructs; (B) Western blot of cell lysates, supernatants and PNGase F treated supernatants from transiently transfected 293T. </plain></SENT>
<SENT sid="569" pm="."><plain>Cells were transfected with pVAX (empty vector), FliC, FliC Δ174–400 or FliC Δ220–320. </plain></SENT>
<SENT sid="570" pm="."><plain>Samples were collected 48 h post transfection. </plain></SENT>
<SENT sid="571" pm="."><plain>Blots were probed with a mouse anti-FLAG tag antibody to detect FLAG-tagged flagellin proteins. </plain></SENT>
<SENT sid="572" pm="."><plain>A mouse anti-tubulin antibody, was used to detect tubulin as a loading control; (C) Measurement of relative secretion level of FLAG-tagged proteins using capture ELISA. </plain></SENT>
<SENT sid="573" pm="."><plain>Supernatants from transiently transfected 293T were applied to anti-FLAG tag antibody coated plates and probed with a horseradish peroxidase (HRP) conjugated mouse anti-FLAG tag antibody. </plain></SENT>
<SENT sid="574" pm="."><plain>Results shown represent the mean of 4 different experiments where FliC is set to a value of 1. </plain></SENT>
<SENT sid="575" pm="."><plain>Error bars represent standard error of the mean; (D) Relative TLR5 agonist activity of secreted FliC proteins. </plain></SENT>
<SENT sid="576" pm="."><plain>Normalized supernatants from transiently transfected 293T were diluted 1:100 and added to HEK-Blue-hTLR5 cells. </plain></SENT>
<SENT sid="577" pm="."><plain>After 20 h incubation, the quantity of secreted embryonic alkaline phosphatase (SEAP) produced was determined using a colorimetric enzyme assay. </plain></SENT>
<SENT sid="578" pm="."><plain>Relative quantities, presented as response ratios, are indicative of TLR5 agonist activity. </plain></SENT>
<SENT sid="579" pm="."><plain>Results shown represent the mean of 4 different experiments where pVAX is set to a value of 1. </plain></SENT>
<SENT sid="580" pm="."><plain>Error bars represent standard error of the mean. </plain></SENT>
</text></p></caption><graphic xlink:href="viruses-10-00100-g002"/></fig></SecTag><SecTag type="FIG"><fig id="viruses-10-00100-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p><text><SENT sid="581" pm="."><plain>Residues QRVRELAV (89–96) of FliC are required for TLR5 agonist activity. </plain></SENT>
<SENT sid="582" pm="."><plain>(A) Schematic representation of FliC constructs; (B) Western blots of cell lysates and supernatants from transiently transfected 293T. </plain></SENT>
<SENT sid="583" pm="."><plain>Cells were transfected with pVAX, FliC, FliC Δ174–400, FliC Δ220–320, FliC Δ89–96, FliC Δ89–96 Δ174–400 or FliC Δ89–96 Δ220–320. </plain></SENT>
<SENT sid="584" pm="."><plain>Blots were probed with a mouse anti-FLAG tag antibody to detect FLAG-tagged flagellin proteins. </plain></SENT>
<SENT sid="585" pm="."><plain>A mouse anti-tubulin antibody, was used to detect tubulin as a loading control; (C) Relative TLR5 agonist activity of secreted FliC proteins. </plain></SENT>
<SENT sid="586" pm="."><plain>Normalized supernatants from transiently transfected 293T were diluted 1:100 and added to HEK-Blue-hTLR5 cells. </plain></SENT>
<SENT sid="587" pm="."><plain>After 20 h incubation, the quantity of SEAP produced was determined using a colorimetric enzyme assay. </plain></SENT>
<SENT sid="588" pm="."><plain>Relative quantities, presented as response ratios, are indicative of TLR5 agonist activity. </plain></SENT>
<SENT sid="589" pm="."><plain>Results shown represent the mean of 4 different experiments where pVAX is set to a value of 1. </plain></SENT>
<SENT sid="590" pm="."><plain>Error bars represent standard error of the mean; (D) Induction of IL-1β transcription detected by RT-PCR and gel electrophoresis. </plain></SENT>
<SENT sid="591" pm="."><plain>Normalized supernatants from transiently transfected 293T were diluted 1:100 and added to THP-1 or J774A.1 cells. </plain></SENT>
<SENT sid="592" pm="."><plain>Cells were incubated for 2 h then harvested and RNA was obtained for RT-PCR with IL-1β specific primers. </plain></SENT>
<SENT sid="593" pm="."><plain>Cells treated with LPS or with supernatant from empty vector transfected cells were used as induced and non-induced controls, respectively. </plain></SENT>
<SENT sid="594" pm="."><plain>RT-PCR with GAPDH specific primers was used as an internal control. </plain></SENT>
<SENT sid="595" pm="."><plain>To exclude potential DNA carry-over and amplification or contamination, control reactions omitting the RT enzyme (-RT) or omitting input RNA (negative control) are also shown. </plain></SENT>
</text></p></caption><graphic xlink:href="viruses-10-00100-g003"/></fig></SecTag><SecTag type="FIG"><fig id="viruses-10-00100-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p><text><SENT sid="596" pm="."><plain>FliC Δ174-400 with gp41607-683 inserted at its N-terminus is secreted and maintains TLR5 agonist activity. </plain></SENT>
<SENT sid="597" pm="."><plain>(A) Schematic representation of flagellin constructs; (B) Western blot of cell lysates and supernatants from transiently transfected 293T. </plain></SENT>
<SENT sid="598" pm="."><plain>Cells were transfected with pVAX, FliC, FliC Δ174–400, FliC Δ220–320, gp41607–683 FliC, gp41607–683 FliC Δ174–400, gp41607–683 FliC Δ220–320, FliC Δ174-[gp41607–683]-400, FliC Δ220-[gp41607–683]-320, FliC gp41607–683, FliC Δ174–400 gp41607–683 or FliC Δ220–320 gp41607–683. </plain></SENT>
<SENT sid="599" pm="."><plain>Samples were collected 48 h post transfection. </plain></SENT>
<SENT sid="600" pm="."><plain>Blots were probed with a mouse anti-FLAG tag antibody to detect FLAG-tagged flagellin proteins. </plain></SENT>
<SENT sid="601" pm="."><plain>A mouse anti-tubulin antibody, was used to detect tubulin as a loading control; (C) Measurement of relative secretion level of FLAG-tagged proteins using capture ELISA. </plain></SENT>
<SENT sid="602" pm="."><plain>Supernatants from transiently transfected 293T were applied to anti-FLAG tag antibody coated plates and probed with an HRP conjugated mouse anti-FLAG tag antibody. </plain></SENT>
<SENT sid="603" pm="."><plain>Results shown represent the mean of 3 different experiments where FliC is set to a value of 1. </plain></SENT>
<SENT sid="604" pm="."><plain>Error bars represent standard error of the mean; (D) Relative TLR5 agonist activity of secreted FliC proteins. </plain></SENT>
<SENT sid="605" pm="."><plain>Normalized supernatants from transiently transfected 293T were diluted 1:100 and added to HEK-Blue-hTLR5 cells. </plain></SENT>
<SENT sid="606" pm="."><plain>After 20 h incubation, the quantity of SEAP produced was determined using a colorimetric enzyme assay. </plain></SENT>
<SENT sid="607" pm="."><plain>Relative quantities, presented as response ratios, are indicative of TLR5 agonist activity. </plain></SENT>
<SENT sid="608" pm="."><plain>Results shown represent the mean of 3 different experiments where pVAX is set to a value of 1. </plain></SENT>
<SENT sid="609" pm="."><plain>Error bars represent standard error of the mean. </plain></SENT>
</text></p></caption><graphic xlink:href="viruses-10-00100-g004a"/><graphic xlink:href="viruses-10-00100-g004b"/></fig></SecTag><SecTag type="FIG"><fig id="viruses-10-00100-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p><text><SENT sid="610" pm="."><plain>FliC Δ174–400 gp41607–683 and gp41607–683 have similar gp41 antigenicity. </plain></SENT>
<SENT sid="611" pm="."><plain>(A) Western blot of cell lysates, supernatants and PNGase F treated supernatants from transiently transfected 293T. </plain></SENT>
<SENT sid="612" pm="."><plain>Cells were transfected with pVAX, FliC Δ174–400, FliC Δ174–400 gp41607–683 or gp41607–683. </plain></SENT>
<SENT sid="613" pm="."><plain>Samples were collected 48 h post transfection. </plain></SENT>
<SENT sid="614" pm="."><plain>Blots were probed with a mouse anti-FLAG tag antibody to detect FLAG-tagged flagellin proteins. </plain></SENT>
<SENT sid="615" pm="."><plain>A mouse anti-tubulin antibody, was used to detect tubulin as a loading control; (B) Schematic representation of 4E10 and 10E8 binding sites; (C) Binding of MPER-specific broadly neutralizing antibodies (bnAB) to FliC Δ174–400 gp41607–683 and gp41607–683. </plain></SENT>
<SENT sid="616" pm="."><plain>Normalized supernatants from transiently transfected 293T were added to streptavidin coated plates. </plain></SENT>
<SENT sid="617" pm="."><plain>Captured antigen was probed with either 10E8 or 4E10 antibodies, then an AP-conjugated mouse anti-human IgG secondary antibody was used to detect antigen-bound 10E8 and 4E10. </plain></SENT>
<SENT sid="618" pm="."><plain>Binding was measured using a fluorescent AP substrate assay and further normalized to levels of captured antigen in each well. </plain></SENT>
<SENT sid="619" pm="."><plain>Results shown represent the mean of 3 different experiments where gp41607–683 is set to a value of 1. </plain></SENT>
<SENT sid="620" pm="."><plain>Error bars represent standard error of the mean. </plain></SENT>
</text></p></caption><graphic xlink:href="viruses-10-00100-g005"/></fig></SecTag><SecTag type="FIG"><fig id="viruses-10-00100-f006" orientation="portrait" position="float"><label>Figure 6</label><caption><p><text><SENT sid="621" pm="."><plain>FliCΔ174–400 augments HIV-1 gp41607–683 immunogenicity. </plain></SENT>
<SENT sid="622" pm="."><plain>(A) Detection of HIV-1 gp41607–683 binding antibodies in vaccinated mice. </plain></SENT>
<SENT sid="623" pm="."><plain>Female BALB/c mice (10 mice per experimental arm) were injected intramuscularly with either pVAX (empty vector) or DNA vaccines FliCΔ174–400 gp41607–683 or gp41607–683 (50 μL in each hind leg at a concentration of 1 μg/μL). </plain></SENT>
<SENT sid="624" pm="."><plain>Two weeks following the 4th vaccination, mouse serum (1:200 dilution) was analyzed for a gp41607–683 specific IgG response. </plain></SENT>
<SENT sid="625" pm="."><plain>Each point represents the mean absorbance value obtained from individual mouse serum (each analyzed in duplicate). </plain></SENT>
<SENT sid="626" pm="."><plain>Horizontal bars represent average values per vaccine group and error bars represent +/− standard error of the mean. </plain></SENT>
<SENT sid="627" pm="."><plain>Significance was determined using an unpaired t-test with ** indicating a p value &lt; 0.01; (B) Detection of antibodies binding C-terminal residues of HIV-1 gp41607–683. </plain></SENT>
<SENT sid="628" pm="."><plain>Mouse sera from the mice vaccinated with FliCΔ174–400 gp41607–683 were analyzed for an MPER-specific IgG response by comparing binding to gp41607–683 (containing the entire MPER) and gp41607–671 (lacking the twelve C-terminal residues of MPER). </plain></SENT>
<SENT sid="629" pm="."><plain>Vertical bars graphs represent the mean absorbance value obtained for pooled sera (n = 10 mice) analyzed in duplicate. </plain></SENT>
<SENT sid="630" pm="."><plain>Error bars represent standard error of the mean. </plain></SENT>
</text></p></caption><graphic xlink:href="viruses-10-00100-g006"/></fig></SecTag><SecTag type="FIG"><fig id="viruses-10-00100-f007" orientation="portrait" position="float"><label>Figure 7</label><caption><p><text><SENT sid="631" pm="."><plain>Deletion of FliC residues 89–96 results in a reduced adjuvant effect on HIV-1 gp41607–683 immunogenicity. </plain></SENT>
<SENT sid="632" pm="."><plain>Female BALB/c mice (10 mice per experimental arm) were injected intramuscularly with either pVAX (empty vector) or DNA vaccines FliCΔ174–400 gp41607–683 or FliC Δ89–96 Δ174–400 gp41607–683 (50 μL in each hind leg at a concentration of 1 μg/μL). </plain></SENT>
<SENT sid="633" pm="."><plain>Two weeks following the 4th vaccination, mouse serum (1:200 dilution) was analyzed for a gp41607–683 specific IgG response. </plain></SENT>
<SENT sid="634" pm="."><plain>Each point represents the mean absorbance value obtained from individual mouse serum (each with two replicates per mouse). </plain></SENT>
<SENT sid="635" pm="."><plain>Horizontal bars represent average values per vaccine group and error bars represent standard error of the mean. </plain></SENT>
<SENT sid="636" pm="."><plain>Significance was determined using an unpaired t-test with ** indicating a p value &lt; 0.01. </plain></SENT>
</text></p></caption><graphic xlink:href="viruses-10-00100-g007"/></fig></SecTag></floats-group></article>
